Furuya C, Hashimoto Y, Morishita S, Fukuda Y, Inano T, Ochiai T, Shirane S, Edahiro Y, Araki M, Ando M, Komatsu N, A higher JAK2 V617F allele burden may be a risk factor for hemorrhagic events in younger patients with polycythemia vera, Hematology, 2024 ;29(1) :2427905.
Abu-Zeinah G, Qin A, Gill H, Komatsu N, Mascarenhas J, Shih WJ, Zagrijtschuk O, Sato T, Shimoda K, Silver RT, Mesa R, A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis, Ann Hematol, 2024 ;103(9) :3573-3583.
Yamazaki S, Mabuchi Y, Kimura T, Suto EG, Hisamatsu D, Naraoka Y, Kondo A, Azuma Y, Kikuchi R, Nishikii H, Morishita S, Araki M, Komatsu N, Akazawa C, Activated mesenchymal stem/stromal cells promote myeloid cell differentiation via CCL2/CCR2 signaling, Stem Cell Reports, 2024 ;19(3) :414-425.
Yoshida C, Takaku T, Asciminib: the next-generation bullet for first-line treatment of chronic myeloid leukemia, Med, 2024 ;5(8) :856-858.
Homma Y, Yamasaki T, Tashiro K, Okada Y, Shirogane Y, Watari T, Hayashi K, Baba T, Nagata K, Yanagisawa N, Ohtsu H, Fujiwara N, Ando J, Yamaji K, Tamura N, Ishijima M, Autologous concentrated bone marrow injection for precollapse osteonecrosis of the femoral head concurrent with contralateral total hip arthroplasty: protocol for a clinical trial, BMJ open, 2024 ;14(5) e082243. pii: e082243.
Kaito S, Najima Y, Sadato D, Hirama C, Kishida Y, Nagata A, Konishi T, Yamada Y, Kurosawa S, Yoshifuji K , Shirane S, Shingai N, Toya T, Shimizu H , Haraguchi K, Kobayashi T , Harada H, Okuyama Y, Yuka Harada Y Doki N, Azacitidine and gemtuzumab ozogamicin as post-transplant maintenance therapy for high-risk hematologic malignancies, Bone Marrow Transplant., 2024 ;59(8) :1169-1175.
Nitta H, Takizawa H, Mitsumori T, Iizuka-Honma H, Ochiai T, Furuya C, Araki Y, Fujishiro M, Tomita S, Hashizume A, Sawada T, Miyake K, Okubo M, Sekiguchi Y, Ando M, Noguchi M, A New Histology-Based Prognostic Index for Aggressive T-Cell lymphoma: Preliminary Results of the "TCL Urayasu Classification", J Clin Med, 2024 ;13(13) :3870.
Iriyama N, Iwanaga E, Kimura Y, Watanabe N, Ishikawa M, Nakayama H, Sato E, Tabayashi T, Mitsumori T, Takaku T, Nakazato T, Tokuhira M, Fujita H, Ando M, Hatta Y, Kawaguchi T,Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group,Int J Hematol, 2024 ;120(1) :60-70.
Watanabe N, Harada S, Sato S, Fukuda Y, Tanaka Y, Yanashima K, Sato E, Taniguchi D, Tomizawa Y, Hattori N, Ando M, Chromosomal Abnormalities as a Predisposition to Secondary Neurolymphomatosis in Patients with Diffuse Large B-Cell Lymphoma: A Report of Two Cases and a Literature Review, Case Rep Oncol, 2024 ;17 :1201–1207.
Sugimoto Y, Nagaharu K, Ohya E, Ohishi K, Tawara I, Ito T, Gotoh A, Nakamae M, Kimura F, Koike M, Kirito K, Wada H, Usuki K, Tanaka T, Mori T, Wakita S, Saito T, Saito M A, Shimoda K, Kurokawa T, Tomita A, Edahiro Y, Hashimoto Y, Kiyoi H, Akashi K, Matsumura I, Takenaka K, Komatsu N, Clinical characteristics in adolescents and young adults with polycythemia vera and essential thrombocythemia in Japan, Int J Hematol, 2024 ;120(6) :684-693.
Nagaharu K, Ohya E, Edahiro Y, Hashimoto Y, Ito T, Gotoh A, Nakamae M, Kimura F, Koike M, Kirito K, Wada H, Usuki K, Tanaka T, Mori T, Wakita S, Saito I T, Saito M A, Shimoda K, Kurokawa T, Tomita A, Kiyoi H, Akashi K, Matsumura I, Takenaka K, Komatsu N, Ohishi K, Tawara I, Sugimoto Y, Correction to: Predictive significance of high neutrophil ratio for thrombosis in myeloproliferative neoplasms: JSH-MPN-R18 subanalysis, Ann Hematol, 2024 ;103(10) :4349-4350.
Hidaka M, Inokuchi K, Uoshima N, Takahashi N, Yoshida N, Ota S, Nakamae H, Iwasaki H, Watanabe K, Kosaka Y, Komatsu N, Meguro K, Najima Y, Eto T, Kondo T, Kimura S, Yoshida C, Ishikawa Y, Sawa M, Hata T, Horibe K, Iida H, Shimomura T, Dobashi N, Sugiura I, Makiyama J, Miyagawa N, Sato A, Ito R, Matsumura I, Kanakura Y, Naoe T, Development and evaluation of a rapid one-step high sensitivity real-time quantitative PCR system for minor BCR-ABL (e1a2) test in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL), Jpn J Clin Oncol., 2024 ;54(2) :153-159.
Ochiai T, Yasuda H, Akiba H, Ashizawa K, Hosoya E, Ando J, Miyake S, Ando M, Ectopic band 3 expression as a cause of mature ovarian teratoma-associated secondary autoimmune hemolytic anemia, Int J Lab Hematol, 2024 ;46(4) :744-746.
Ito K, Akizawa T, Arita K, Mitobe Y, Komatsu N, Effect of ferric citrate hydrate on fibroblast growth factor 23 and platelets in non-dialysis-dependent chronic kidney disease and non-chronic kidney disease patients with iron deficiency anemia, Clin Exp Nephrol, 2024 ;28(7) :636-646.
Shimoda K, Qin A, Komatsu N, Kirito K.Shimoda K, Qin A, Komatsu N, Kirito K.Shimoda K, Qin A, Komatsu N, Kirito K, Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b, Int J Hematol, 2024 ;120(2) :151-156.
Kaito Y, Sugimoto E, Nakamura F, Tsukune Y, Sasaki M, Yui S, Yamaguchi H, Goyama S, Nannya Y, Mitani K, Tamura H, Imai Y, Immune checkpoint molecule DNAM-1/CD112 axis is a novel target for natural killer-cell therapy in acute myeloid leukemia, Haematologica, 2024 ;109(4) :1107-1120.
Furuya C, Morishita S, Hashimoto Y, Inano T, Ochiai T, Shirane S, Edahiro Y, Araki M, Ando M, Komatsu N, Impact of non-driver gene mutations on thrombo-haemorrhagic events in ET patients, Br J Haematol, 2024 ;204(1) :221-228.
Okuda M, Araki M, De Marchi F, Morishita S, Imai M, Fukuda H, Ando M,Komatsu N, Involvement of CREB3L1 in erythropoiesis induced by JAK2 exon 12 mutation, Exp Hematol, 2024 ;139 :104636.
Furukawa Y, Ando J, Ishii M, Kinoshita S, Goto A, Tachibana K, Azusawa Y, Kato T, Izumi Y, Hosoya E, Uchimura A, Inano T, Shirane S, Tsukune Y, Takaku T, Hamano Y, Ando M, L-asparaginase monotherapy as an encouraging approach towards acute fulminant chronic active Epstein-Barr virus infection, Br J Haematol, 2024 ;205(4) :1610-1614.
Miyakawa Y, Sato E, Ogawa Y, Nishimura J, Nishimi M, Kawaguchi O, Tahara S, Yamaguchi M, Long term safety profile of sutimlimab in adult Japanese patients with cold agglutinin disease, Int J Hematol, 2024 ;120 :656–664.
Rai S, W S Kim, Ando K, Choi I, Izutsu K, Tsukamoto N, Maruyama D, Tsukasaki K, Kuroda J, Ando J, Hidaka M, Koh Y, Kato H, Uchida T, D H Yang, Ishitsuka K, Ishizawa K, J S Kim, H G Lee, Minami H, H S Eom, Kurosawa M, J H Lee, J S Lee, W S Lee, Nagai H, Shindo T, D H Yoon, Yoshida S, Gillings M, Onogi H, Tobinai K, Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results, Haematologica, 2024 ;109(10) :3357-3362.
Kirito K, Sugimoto Y, Gotoh A, Takenaka K, Ichii M, Inano T, Shirane S, Ito M, Zagrijtschuk O, Qin A, Kawase H, Sato T, Komatsu N, Shimoda K, Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera, Int J Hematol, 2024 ;120(6) :675-683.
Shimoda K, Komatsu N, Matsumura I, Ikeda K, Hino M, Hidaka M, Maeda Y, Kondo T, Fujisaki T, Shoshi K, Azuma K, Fukushima R, Kawashima J, Kosugi H, Momelotinib versus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: an efficacy/safety analysis in the Japanese subgroup of the phase 3 randomized SIMPLIFY-1 trial, Int J Hematol, 2024 ;120(3) :314-324.
Yasuda H, Kaga N, Taka H, Ochiai T, Yamana T, Miura Y, Ishii M, Sasaki M, Ando J, Ando M, Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma, Cancer Chemother Pharmacol, 2024 ;93(3) :265-268.
Nagaharu K, Ohya E, Edahiro Y, Hashimoto Y, Ito T, Gotoh A, Nakamae M, Kimura F, Koike M, Kirito K, Wada H, Usuki K, Tanaka T, Mori T, Wakita S, Saito I T, Saito M A, Shimoda K, Kurokawa T, Tomita A, Kiyoi H, Akashi K, Matsumura I, Takenaka K, Komatsu N, Ohishi K, Tawara I, Sugimoto Y, Predictive significance of high neutrophil ratio for thrombosis in myeloproliferative neoplasms: JSH-MPN-R18 subanalysis, Ann Hematol, 2024 ;103(9) :3535-3541.
Shibayama H, Itagaki M, Handa H, Yokoyama A, Saito A, Kosugi S, Ota S, Yoshimitsu M, Tanaka Y, Kurahashi S, Fuchida SI, Iino M, Shimizu T, Moriuchi Y, Toyama K, Mitani K, Tsukune Y, Kada A, Tamura H, Abe M, Iwasaki H, Kuroda J, Takamatsu H, Sunami K, Kizaki M, Ishida T, Saito T, Matsumura I, Akashi K, Iida S, Primary analysis of a prospective cohort study of Japanese patients with plasma cell neoplasms in the novel drug era (2016-2021), Int J Hematol, 2024 ;119(6) :707-721.
Honda A, Masuda Y, Oyama Y, Matsuda K, Mizuno H, Saito AM, Katayama Y, Komatsu N, Toyama K, Kurokawa M, Prognostic factors of idiopathic hypereosinophilic syndrome: A nationwide survey in Japan, Br J Haematol, 2024 ;205(3) :967-977.
Edahiro Y, Ochiai T, Hashimoto Y, Ichii M, Okatani T, Omura H, Nakajima K, Sasaki M, Ando J, Takaku T, Koike M, Izumiyama K, Hiraga J, Yano T, Usuki K, Ohtsuka E, Yokoyama K, Oyake T, Takahashi N, Nishida T, Nakao T, Fukuda Y, Akasaka T, Mugitani A, Ando M, Komatsu N, Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in Japan, Hematology, 2024 ;29(1) :2340149.
Kinoshita S, Ishii M, Ando J, Kimura T, Yamaguchi T, Harada S, Takahashi F, Nakashima K, Nakazawa Y, Yamazaki S, Ohshima K, Takahashi K, Nakauchi H, Ando M, Rejuvenated iPSC-derived GD2-directed CART cells harbor robust cytotoxicity against small cell lung cancer, Cancer Res Commun, 2024 ;4(3) :723-737.
Ravzanaadii M, Horiuchi Y, Iwasaki Y, Matsuzaki A, Kaniyu K, Bai J, Konishi A, Ando J, Ando M, Tabe Y, Robustness assessment of an automated AI-based white blood cell morphometric analysis system using different smear preparation methods, Int J Lab Hematol, 2024 ;46(6) :1021-1028.
Uchimura A, Yasuda H, Onagi H, Inano T, Shirane S, Ishii,M, Azusawa Y, Hamano Y, Eguchi H, Arai M, Ando J, Ando M, Successful management of acute graft-versus-host disease with ibrutinib during cord blood transplantation for germline DDX41-mutated acute myeloid leukemia, Heliyon, 2024 ;10(2) :e24801.
Hosoya E, Ando J, Kinoshita S, Furukawa Y, Toyoshima Y, Y Azusawa Y, Mitsumori T, Sato E, Takano H, Tsukune Y, Watanabe N, Takaku T, Yasuda H, Hamano Y, Sasaki M, Nojiri S, Ishii M, Ando M. Eleven cases of laryngeal edema after tisagenlecleucel infusion: a 3-year single center retrospective study of CD19-directed chimeric antigen receptor T-cell therapy for relapsed and refractory B-cell lymphomas, Haematologica, 2024 ;286169.
Edahiro Y, Shirane S, Takeda J, Yasuda H, Inano T, Tsutsui M, Hamano Y, Sasaki M, Ando J, Itakura A, Ando M, Komatsu N, Assessment and management of pregnancy in patients with myeloproliferative neoplasms: Insights from a single-institution study of 29 neonates, Int J Hematol, 2025 ;121(2) :281-283, Epub 2024 Dec 6.
Suzuki K, Watanabe N, Torii S, Arakawa S, Ochi K, Tsuchiya S, Yamada K, Kawamura Y, Ota S, Komatsu N, Shimizu S, Ando M, Takaku T, BCR::ABL1-induced Mitochondrial Morphological Alterations as a Potential Clinical Biomarker in Chronic Myeloid Leukemia, Cancer Sci, 2025 ;116(3) :673-689, Epub 2024 Dec 9
Sato S, Ishii M, Tachibana K, Furukawa Y, Toyota T, Kinoshita S, Azusawa Y, Ando J, Ando M, Establishment of ganglioside GD2-expressing extranodal NK/T cell lymphoma cell line with scRNA-seq analysis, Exp Hematol, 2024 ;130 :104132.
英文症例報告
Asazuma K, Shimomura A, Kawamura Y, Taniyama T, Shimizu C,Case Report of Complete Response to Olaparib in a Patient with Breast Cancer Brain Metastases,Case Rep Oncol, 2024 ;17(1) :773–778.
Furuya C, Yasuda H, Hiki M, Shirane S, Yamana T, Uchimura A, Inano T, Takaku T, Hamano Y, Ando M,Case report: Ensitrelvir for treatment of persistent COVID-19 in lymphoma patients: a report of two cases,Front Immunol, 2024 ;15 :1287300.
Sekiguchi Y, Tsutsumi H, Gomyo A, Kudo M, Maseki N, Iizaki Y, Kawamura M, Kobayashi K, Nitta H, Noguchi M, Wakita S, Yamaguchi H, Kobayashi H,A Case of Relapsed/Refractory CD56-Positive Acute Promyelocytic Leukemia, in Which Complete Molecular Remission Was Achieved Following Combination Therapy with Venetoclax and Azacitidine, Gan To Kagaku Ryoho, 2024 ;51(3) :291-297.
Sekiguchi Y, Tsutsumi H, Kudo M, Maseki N, Iizaki Y, Kawamura M, Kobayashi K, Abe T, Takei D, Nishimura Y, Kanda H, Noguchi M, Kobayashi H, Prognostic Factors in Patients with Acute Myeloid Leukemia Treated with the Combination of Venetoclax plus Azacitidine(VEN+AZA), Gan To Kagaku Ryoho, 2024 ;51(11) :1143-1152.
Ochiai T, Yasuda H, Akiba H, Ashizawa K, Hosoya E, Ando J, Miyake S, Ando M, Ectopic band 3 expression as a cause of mature ovarian teratoma-associated secondary autoimmune hemolytic anemia, Int J Lab Hematol, 2024 ;46(4) :744-746.
Shirane S, Yasuda H, Uchimura A, Mori Y, Inano T, Tsutsui M, Hamano Y, Ando M, Splenic irradiation preceding allogeneic hematopoietic stem cell transplantation as a possible risk factor of sinusoidal obstruction syndrome: a report of three cases, Case Rep Oncol, 2024 ;18(1) :1-6.
国際学会発表
Furuya C, Higher JAK2V617F allele burden is a possible risk factor for hemorrhagic events in younger patients with polycythemia vera, the ESH 10th Translational Research Conference on Myeloproliferative Neoplasms, Mandelieu-La Napoule, France, April 2024.
Ando M, iPSC-derived next-generation T cell therapy for refractory tumors, ISSCR International Symposium Cincinnati, USA, April 2024.
Furukawa Y, Ishii M, Goto A, Kinoshita S, Ando J, Nakauchi H, Ando M,PSC-derived CD4 T cell generation and investigation of CD4/CD8 T cell lineage choice, ISSCR2024, Hamburg, Germany, July 2024.
Suzuki K, Watanabe N, Yamada K, Ando M, Takaku T, Artificial Intelligence-Driven Label-Free Detection of Chronic Myeloid Leukemia Cells from Low-Percentage Samples, ESH-iCMLf 26th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy, Prague, Czech Republic, September 2024.
Suzuki K, Watanabe N, Yamada K, Ando M, Takaku T, Morphological Characteristics of Chronic Myeloid Leukemia Cells as Predictors of Tyrosine Kinase Inhibitor Treatment Efficacy, ESH-iCMLf 26th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy, Prague, Czech Republic, September 2024.
Ando M, iPSC-derived next-generation T cell therapy for virus-associated refractory tumors, ACTO2024, China, October 2024.
Goto A, Ishii M, Kinoshita S, Furukawa Y, Izumi N, Ando J, Nakauchi H, Ando M, iPSC-derived chimeric antigen receptor T cells that originally lack CD5 expression exhibits robust cytotoxicity against T-cell malignancies, 66th ASH Annual Meeting & Exposition, San Diego, CA, December 2024.
Matsuzaki K, Ishii M, Kinoshita S, Goto A, Azusawa Y, Furukawa Y, Ando J, Nakauchi H, Ando M,Preclinical study of HLA class I-edited allogeneic iPSC-derived virus-specific T cells targeting Epstein-Barr virus-associated lymphomas,66th ASH Annual Meeting & Exposition, San Diego, CA, December 2024.
Uchimura A, Hamano Y, Maruyama H, Fukumura Y, Inano T, Shirane S, Ando J, Ando M, Effectiveness of transjugular liver biopsy in diagnosis of refractory ascites after allogeneic HSCT, 第86回日本血液学会学術集会, 京都, 2024年10月11日.
Suzuki K, Takaku T, Watanabe N, Iriyama N, Iwanaga E, Kimura Y,Ishikawa M, Nakayama H, Sato E, Tabayashi T, Mitsumori T, Nakazato T, Tokuhira M, Fujita H, Ando M, Hatta Y, Kawaguchi T, Novel parameters for predicting optimal response in CML treatment, 第86回日本血液学会学術集会, 京都, 2024年10月11日.
Akimoto M, Tokuhira M, Iwanaga E, Iriyama N, Kimura Y,Watanabe N, Ishikawa M, Nakayama H, Nakazato T, Sato E, Tabayashi T, Mitsumori T, Takaku T, Fujita H, Ando M, Kawaguchi T, Real-world data of ponatinib administration among the patients with CML-CP based on CML-CSG database, 第86回日本血液学会学術集会, 京都, 2024年10月11日.
Sheng J, Nagata Y, Marumo A,Sakaguchi M, Arai K,Miyata M, Wakita S, Doki N, Hashimoto A, Kimura S, Ogata M, Uoshima N, Mitsuhashi K, Ando J, Hagihara M, Sato E, Nagao Y, Kanda J, Kako S, Sekiguchi Y, Fukunaga K, Edahiro T,Tashiro H, Satake A, Uchiyama H, Takada S, Nishiyama D, Shono K, Kanda Y, Yamaguchi H, Venetoclax showed overall survival comparable to intensive chemotherapy (IC), superior to reduced IC, 第86回日本血液学会学術集会, 京都, 2024年10月11日.
Kirito K , Sugimoto Y, Gotoh A, Takenaka K, Ichii M, Inano T, Shirane S, Ito M, Zagrijtschuk O, Qin A, Kawase H, Sato T, Komatsu N, Shimoda K, Long-term treatment with ropeginterferon alfa-2b for Japanese patients with polycythemia vera, 第86回日本血液学会学術集会, 京都, 2024年10月12日.
Suzuki K, Watanabe N, Yamada, Ando M, Takaku T, Challenges toward AI-Driven Label-Free Detection of CML Cells, 第86回日本血液学会学術集会, 京都, 2024年10月12日.
Sano Y, Misawa K, Yamada K, Mori Y, Iwao N, Koike M, Takano H, Effectiveness of fostamatinib (FOS) in refractory in immune thrombocytopenia (ITP), 第86回日本血液学会学術集会, 京都, 2024年10月12日.
Suzuki K, Watanabe N, Yamada K, Ando M, Takaku T, Predicting Treatment Efficacy Based on Morphological Characteristics of CML Cells, 第86回日本血液学会学術集会, 京都, 2024年10月12日.
Kurosawa S, Oshima M, Nakajima Y, Takayama N, Sakaida E, Sato E,Doki N, Nishikawa K, Ding Y, Myojo T, Harada Y, Harada H, Iwama A, Transposable elements are differentially expressed in MDS stem cells in a stage-specific manner, 第86回日本血液学会学術集会, 京都, 2024年10月12日.
Sekimoto N, Ota H, Mori M, Morishita S, Inano T, Komatsu N, Development of CREB3L1 testing method for the diagnosis of myeloproliferative neoplasms, 第86回日本血液学会学術集会, 京都, 2024年10月13日.
Tokuhira M, Kimura Y, Iriyama N, Watanabe N, Ishikawa M, Nakayama H, Nakazato T,Sato E, Tabayashi T, Mitsumori T, Akimoto M, Fujita H, Takaku T, Ando M, Iwanaga E, Kawaguchi T, Analysis of very elderly patients (=>75 years) with ND CML-CP who received TKIs, 第86回日本血液学会学術集会, 京都, 2024年10月13日.
Mitsumori T, Iriyama N, Nakazato T, Watanabe N, Takaku T, Ishikawa M,Fujita H, Iwanaga E, Tokuhira M, Sato E, Tabayashi T, Kimura Y, Kawaguchi T, Improvement of diabetes mellitus by dasatinib in patients with CML: a report from CML-CSG, 第86回日本血液学会学術集会, 京都, 2024年10月13日.
Iwanaga E, Iriyama N, Kimura Y, Watanabe N, Ishikawa M, Nakayama H, Nakazato T, Eriko Sato, Tabayashi T, Mitsumori T, Takaku T, Tokuhira M, Akimoto M, Fujita H, Ando M, Kawaguchi T, Outcomes of chronic myeloid leukemia patients with impaired renal function,第86回日本血液学会学術集会, 京都, 2024年10月13日.
Harada S, Tanaka Y, Fukuda Y, Watanabe N, Sato E, Hirano T, Successful treatment with Am80 for relapse and refractory APL complicated by necrotizing fasciitis, 第86回日本血液学会学術集会, 京都, 2024年10月13日.
安藤美樹, iPSC-derived next-generation T cell therapy for refractory tumors, JSH-ASH Joint symposium, 第86回日本血液学会学術集会, 京都, 2024年10月13日.
Kuribara M, Sheng J, Nagata Y, Marumo A, Sakaguchi M, Arai K, Miyata M, Wakita S, Hashimoto A, Kimura S, Ogata M,Uoshima N, Mitsuhashi K, Ando J, Hagihara M,Eriko Sato, Nagao Y, Kanda J, Kako S, Sekiguchi Y, Fukunaga K, Edahiro T, Tashiro H, Satake A, Uchiyama H, Takada S,Nishiyama D, Shono K, Kanda Y, Yamaguchi H, Acute myeloid leukemia with DDX41 variants, 第86回日本血液学会学術集会, 京都, 2024年10月13日.
Ando M, Hosoya E, Kinoshita S, Ishii M, Uchimura A, Inano T, Shirane S, Hamano Y, Ando J, Single-center retrospective study of CD19-directed CAR-T therapy for R/R B-cell lymphomas, 第46回日本造血・免疫細胞療法学会総会, 東京, 2024年3月23日.
安藤美樹, シンポジウム17 Investigator-initiated Phase I trial of iPSC-derived next-generation T cell therapy for cervical cancer, 第23回日本再生医療学会総会, 新潟, 2024年3月22日.
安藤美樹, AASCRMシンポジウムFor the progress of translational research by iPSC technology, 第23回日本再生医療学会総会, 新潟, 2024年3月23日.
安藤美樹, シンポジウム9 細胞療法のさらなる展開 iPSC-derived next-generation T cell therapy for refractory tumors, 第21回日本臨床腫瘍学会学術集会(JSMO), 名古屋, 2024年2月22日.
稲野資明, New Generation Lymphoma Seminar、CAR-T療法後再発に エプコリタマブ が奏効した Primary cutaneous diffuse large B-cell lymphoma, leg type の 一例, ジェンマブ社主催講演会, 2024年11月19日.
稲野資明, Novartis Hematology Web Seminar、PVの実臨床 〜症状管理の重要性〜ノバルティスファーマ社主催講演会, 2024年2月14日.
Ando M, Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma, Springer Health, Web seminar, 1st Oct 2024.
Edahiro Y, Kirito K, Gotoh A, Takenaka K, Sugimoto Y, Komatsu N, Shimoda K, A
cross-sectional survey of symptoms and daily living among patients with polycythemia
vera and their treating physicians in Japan, Hematology, 2023; 28(1): 2227817.
Suzuki K, Watanabe N, Torii S, Arakawa S, Ochi K, Tsuchiya S, Yamada K, Kawamura Y, Ota
S, Komatsu N, Shimizu S, Ando M, Takaku T , Artificial Intelligence Enables the
Label-Free Identification of Chronic Myeloid Leukemia Cells with Mitochondrial
Morphological Alterations, bioRxiv, 2023; doi: 10. 1101/ 2023. 07. 26. 550632.
Edahiro Y, Ochiai T, Hashimoto Y, Morishita S, Shirane S, Inano T, Furuya C, Koike M,
Noguchi M, Usuki K, Shiratsuchi M, Nakajima K, Ohtsuka E, Tanaka H, Kawata E, Nakamae M,
Ueda Y, Aota Y, Sugita Y, Ohara S, Yamasaki S, Asagoe K, Yoshida S, Yamanouchi J, Suzuki
S, Kondo T, Kanisawa Y, Toyama K, Omura H, Mizuchi D, Sakamaki S, Ando M, Komatsu N ,
Clinical characteristics of Japanese patients with Myelodysplastic/myeloproliferative
neoplasm with ring sideroblasts and thrombocytosis, International journal of hematology,
2023; 118: 47-53.
Mori Y, Araki M, Morishita S, Imai M, Edahiro Y, Ito M, Ochiai T, Shirane S, Hashimoto
Y, Yasuda H, Ando J, Ando M, Komatsu N, Clinical features of acquired erythrocytosis:
Low levels of serum erythropoietin in a subset of non-neoplastic erythrocytosis
patients, Cancer Med., 2023; 12(2): 1079-1089.
Tokuhira M, Kimura Y, Tabayashi T, Watanabe N, Tsuchiya S, Takaku T, Iriyama N, Sato E,
Nakazato T, Mitsumori T, Ishikawa M, Fujita H, Kizaki M, Ando M, Hatta Y, Iwanaga E,
Kawaguchi T, Clinical management of second-generation tyrosine kinase inhibitor therapy
in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, focusing
on age and dose effects, Int J Hematol, 2023; 118(2): 210- 220.
Miyake M, Tsuyama N, Togashi Y, Noguchi M, tsukada N, Mishima Y, Takeuchi K,
Eosinophil-rich variant of nodal marginal zone lymphoma: a clinicopathological study of
11 case, Histopathology, 2023; https://doi.org/10.1111/his.14963.
Kaneko T, Miyazaki S, Kurita A, Morimoto R, Tsuchiya S, Watanabe N, Takaku T, Komatsu N,
Minamino T, Endothelial function measured by peripheral arterial tonometry in patients
with chronic myeloid leukemia on tyrosine kinase inhibitor therapy: a pilot study ,
Cardiooncology, 2023; 9(1): 11.
Sato S, Ishii M, Tachibana K, Furukawa Y, Toyota T, Kinoshita S, Azusawa Y, Ando J, Ando
M, Establishment of ganglioside GD2-expressing extranodal NK/T cell lymphoma cell line
with scRNA-seq analysis, Experimental Hematology, 2023; S0301-472X(23)01769-1. doi:
10.1016.
Liu C, Imai M, Edahiro Y, Mano S, Takei H, Nudejima M, Kurose A, Morishita S, Ando M,
Tsuneda S, Araki M, Komatsu N, Establishment of isogenic induced pluripotent stem cells
with or without pathogenic mutation for understanding the pathogenesis of
myeloproliferative neoplasms, Exp Hematol, 2023; 118: 12-20.
Tsuchiya K, Kimura K, Ai T, Yamamoto T, Nagasaka K, Takemura H, Edahiro Y, Saito K,
Horiuchi Y, Misawa S, Takaku T, Ando J, Ando M, Miida T, Uchihashi K, Tabe Y, Evaluation
of bone marrow aspirates using the automated hematology analyzer Sysmex XN-3000,
International journal of laboratory hematology, 2023; 45(4); 460-468. doi: 10. 1111/
ijlh. 14058.
Yasuda H, Ando J, Yoshida S, Ota Y, Komatsu N, Ando M, Diffuse Large B-cell Lymphoma
with Adrenal Involvement Presenting as Other Iatrogenic Immunodeficiency-associated
Lymphoproliferative Disorders: Sustained Remission with Methotrexate Termination Alone
in Two Cases, Intern Med., 2023; 62(4): 601-604.
Iizuka-Honma H, Mitsumori T, Yoshikawa S, Takizawa H, Noguchi M, Factors Associated With
Survival in Patients With End-of-Life Hematological Malignancies Who Received
Chemotherapy: A Retrospective Single-Institution Study, Am J Hosp Palliat Care, 2023;
40(8): 812-819.
Furuya C, Morishita S, Hashimoto Y, Inano T, Ochiai T, Shirane S, Edahiro Y, Araki M,
Ando M, Komatsu N, Impact of non-driver gene mutations on thrombo-haemorrhagic events in
ET patients, British Journal of Haematology, 2023; doi: 10.1111.
Furukawa Y*, Ishii M*, Ando J, Ikeda K, Igarashi J K, Kinoshita S, Azusawa Y, Toyota T,
Honda T, Nakanishi M, Ohshima K, Masuda A, Yoshida E, Kitade M, Porteus M, Terao Y,
Nakauchi H, Ando M *co-first author, iPSC-derived hypoimmunogenic tissue resident memory
T cells mediate robust anti-tumor activity against cervical cancer, Cell Reports
Medicine, 2023; 4(12): 101327. doi: 10.1016.
Tsuchiya S, Takaku T, Watanabe N, Iriyama N, Kimura Y, Iwanaga E, Sugimoto KJ, Mitsumori
T, Ishikawa M, Nakazato T, Fujita H, Sato E, Hatta Y, Asou N, Kizaki M, Tokuhira M, Ando
M, Kawaguchi T, Management and Risk Factors for Pleural Effusion in Japanese Patients
with Chronic Myeloid Leukemia Treated with First-line Dasatinib in Real-world Clinical
Practice, Intern Med., 2023; 62(22): 3299-3303.
Furuya C, Hashimoto Y, Morishita S, Inano T, Ochiai T, Shirane S, Edahiro Y, Araki M,
Ando M, Komatsu N , MPL gene mutation is a possible risk factor for thrombosis in
patients with essential thrombocythemia in Japan, Hematology, 2023; 28(1): 1-7.
Wakita.S, Marumo A, Morita K, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori
S, Satake A, Usuki K, Ueki T, Uoshima N, Kobayashi Y, Kawata E, Nakayama K, Nagao Y,
Shono K, Shibusawa M, Tadokoro J, Hagihara M, Uchiyama H, Uchida N, Kubota Y, Kimura S,
Nagoshi H, Ichinohe T, Kurosawa S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M,
Mitsuhashi K, Ando J, Tashiro H, Sakaguchi M, Yui S, Arai K, Kitano T, Miyata M, Arai H,
Kanda M, Itabashi K, Fukuda T, Kanda Y, Yamaguchi H, Mutational analysis of DNMT3A
improves the prognostic stratification of patients with acute myeloid leukemia, Cancer
science, 2023; 114(4): 1297-1308. doi: 10.1111/cas.15720.
Shide K, Takenaka K, Kitanaka A, Numata A, Kameda T, Yamauchi T, Inagaki A, Mizuno S,
Takami A, Ito S, Hagihara M, Usuki K, Maekawa T, Sunami K, Ueda Y, Tsutsui M, Ando M,
Komatsu N, Ozawa K, Kurokawa M, Arai S, Mitani K, Akashi K, Shimoda K, Nationwide
prospective survey of secondary myelofibrosis in Japan: superiority of DIPSS-plus to
MYSEC-PM as a survival risk model, Blood Cancer Journal, 2023; 13(1): 110. doi:
10.1038/s41408-023-00869-9.
Morishita S, Hashimoto Y, Furuya C, Edahiro Y, Ochiai T, Shirane S, Inano T, Yasuda H,
Ando M, Araki M, Komatsu N, Non-driver gene mutation analysis in a large cohort of
polycythemia vera and essential thrombocythemia, Eur J Haematol, 2023; 110(2): 131-136.
Rai S , Won Seog Kim, Ando K, Choi I, Izutsu K, Tsukamoto N, Yokoyama M, Tsukasaki K,
Kurod J, Ando J, Hidaka M, Koh Y, Shibayama H, Uchida T, Deok Hwan Yang, Ishitsuka K,
Ishizawa K, Jin Seok Kim, Hong Ghi Lee, Minami H, Hyeon Seok Eom, Kurosawa M, Jae Hoon
Lee, Jong Seok Lee, Won Sik Lee, Nagai H, Shindo T, Dok Hyun Yoon, Yoshida S, Gillings
M, Onogi H, Tobinai K, Oral HDAC inhibitor tucidinostat in patients with relapsed or
refractory peripheral T-cell lymphoma: phase IIb results, Haematologica, 2023; 108(3);
811- 821. doi: 10.3324/ haematol. 2022. 280996.
Ogama Y, Kumagai Y, Komatsu N, Araki M, Masubuchi N, Akiyoshi H, Matsuura T, Kirisako H,
Kyoya A, Nomura F, Ohira Y, Yokokawa T, Yamamoto Y, Phase 1 Clinical Trial of PPMX-T003,
a Novel Human Monoclonal Antibody Specific for Transferrin Receptor 1, to Evaluate Its
Safety, Pharmacokinetics, and Pharmacodynamics, Clin Pharmacol Drug Dev, 2023; 12(6):
579-587.
Yasuda H, Kaga N, Taka H, Ochiai T, Yamana T, Miura Y, Ishii M, Sasaki M, Ando J, Ando
M, Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large
B-cell lymphoma, Cancer chemotherapy and pharmacology, 2023; doi:
10.1007/s00280-023-04593-w.
Nitta H, Takizawa H, Mitsumori T, Iizuka-Honma H, Araki Y, Fujishiro M, Tomita S,
Kishikawa S, Hashizume A, Sawada T, Okubo M, Sekiguchi Y, Ando M, Noguchi M, Possible
New Histological Prognostic Index for Large B-Cell Lymphoma, J Clin Med., 2023; 12:
6324.
Shide K, Takenaka K, Kitanaka A, Numata A, Kameda T, Yamauchi T, Inagaki A, Mizuno S,
Takami A, Ito S, Hagihara M, Usuki K, Maekawa T, Sunami K, Ueda Y, Tsutsui M, Ando M,
Komatsu N, Ozawa K, Kurokawa M, Arai S, Mitani K, Akashi K, Shimoda K, Real-world
clinical characteristics of post-essential thrombocythemia and post-polycythemia vera
myelofibrosis, Ann Hematol, 2023; 103(1): 97-103. doi: 10.1007/s00277-023-05528-4.
Furuya C, Hashimoto Y, Morishita S, Inano T, Ochiai T, Shirane S, Edahiro Y, Araki M,
Ando M, Komatsu N, Reevaluation of cardiovascular risk factors for thrombotic events in
580 Japanese patients with essential thrombocythemia, Journal of Thrombosis and
Thrombolysis, 2023; 55(2): 263-272.
Jo T, Yoshihara S, Okuyama Y, Fujii K, Henzan T, Kahata K, Yamazaki R, Takeda W, Umezawa
Y, Fukushima K, Ashida T, Yamada-Fujiwara M, Hanajiri R, Yonetani N, Tada Y, Shimura Y,
Nishikii H, Shiba N, Mimura N, Ando J, Sato T, Nakashima Y, Ikemoto J, Iwaki K, Fujiwara
S, Ri M, Nagamura-Inoue T, Tanosaki R, Arai Y, Risk factors for CAR-T cell manufacturing
failure among DLBCL patients: A nationwide survey in Japan, British journal of
haematology, 2023; 202(2): 256-266. doi: 10.1111/ bjh. 18831.
Takizawa H, Araki Y, Fujishiro M, Tomita S, Kishikawa S, Hashizume A, Mitsumori T, Nitta
H, Iizuka-Honma H, Sawada T, Okubo M, Sekiguchi Y, Ando M, Noguchi M, Role of TGF-beta1
and TNF-alpha1 produced by neoplastic cells in the pathogenesis of fibrosis in patients
with hematologic neoplasms, J Clin Exp Hematop, 2023; 63: 83-89.
Pecquet C, Papadopoulos N, Balligand T, Chachoua I, Tisserand A, Vertenoeil G,
Nédélec A, Vertommen D, Roy A, Marty C, Nivarthi H, Defour JP, El-Khoury
M, Hug E, Majoros A, Xu E, Zagrijtschuk O, Fertig TE, Marta DS, Gisslinger H, Gisslinger
B, Schalling M, Casetti IC, Rumi E, Pietra D, Cavalloni C, Arcaini L, Cazzola M, Komatsu
N, Kihara Y, Sunami Y, Edahiro Y, Araki M, Lesyk R, Buxhofer-Ausch V, Heibl S, Pasquier
F, Plo I, Vainchenker W, Kralovics R, Constantinescu SN, Secreted Mutant Calreticulins
As Rogue Cytokines in Myeloproliferative Neoplasms, Blood, 2023; 141(8): 917-929.
Kinoshita R, Ishibashi M, Handa H, Sasaki M, Imai Y, Tanaka N, Ito S, Sunakawa-Kii M,
Kaito Y, Asayama T, Komatsu N, Tanaka J, Odajima T, Sugimori H, Yamaguchi H, Inokuchi K,
Tamura H, The levels of serum soluble CD86 are correlated with the expression of CD86
variant 3 gene and are prognostic indicators in patients with myeloma, Exp Hematol,
2023; 121: 38-47.e2.
Sekiguchi Y, Tsutsumi H, Gomyo A, Kudo M, Iizaki Y, Maseki N, Kawamura M, Kobayashi K,
Nishimura Y, Kanda H, Nitta H, Noguchi M, Kobayashi H, Use of R-mini-CHP in combination
with polatuzumab vedotin (pola-R-mini-CHP) as the primary treatment in ≥80-year-old
cases with diffuse large B-cell lymphoma, J Clin Exp Hematop, 2023; 63: 262-265.
Asada N, Ando J, Takada S, Yoshida C, Usuki K, Shinagawa A, Ishizawa K, Miyamoto T, Iida
H, Dobashi N, Okubo S, Honda H, Soshin T, Nishimura Y, Tsutsui A, Mukai H, Yamamoto K,
Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid
leukemia ineligible for intensive chemotherapy: an expanded access study in Japan,
Japanese journal of clinical oncology, 2023; 53(7): 595-603. doi: 10. 1093/ jjco/
hyad027.
英文総説
Noguchi M, My 40-year Career as a Hematologist – Facing Clinical Challenges and
Changing My Research– Focus from Glycolipids to Therapy Resistance–. ,
Juntendo Medical Journal, 2023; 69(4): 293-299
Morishita S, Komatsu N, Diagnosis- and Prognosis-Related Gene Alterations in
BCR::ABL1-Negative Myeloproliferative Neoplasms, Int J Mol Sci, 2023; 24(16): 13008
英文症例報告
Iizuka-Honma H, Takizawa H, Nitta H, Mitsumori T, Noguchi M, Development of rapidly
fatal TAFRO syndrome-like features in a patient with essential thrombocythemia, J Clin
Exp Hematop, 2023; 63(1): 32-36.
Higo R, Kojima M, Itoha S, Noguchi M, Izumi H, Takeuchi K, Primary diffuse large B-cell
lymphoma of the Larynx. , Auris Nasus Larynx, 2023; 50(4): 632-636.
Iizuka-Honma H, Takizawa H, Mitsumori H, Okura H, Ishii H, Noguchi M , Refractory
Primary Vitreoretinal Lymphoma Involving the Spinal Cord with a Temporary Complete
Response to Tirabrutinib: A Case Report, Intern Med., 2023; 62(3): 459-463.
Yasuda H, Hoshino Y, Ando J, Miyachi M, Osawa M, Hattori N, Ando M, Vitamin B6
Deficiency Polyneuropathy and Dermatitis, Am J Med., 2023; 136(1): e10-e11.
国際学会発表
Suzuki K, Watanabe N, Ochi K, Torii S, Yamada K, Kawamura Y, Shimizu S, Komatsu N, Ando
M, Takaku T , Artificial Intelligence-Driven “Ghost Cytometry” Enables
Label-Free Identification of Chronic Myeloid Leukemia Cells Through Mitochondrial
Morphological Alterations, 25th Annual John Goldman Conference on Chronic Myeloid
Leukemia: Biology and Therapy, Mandelieu-La Napoule, France, October 7, 2023.
Ando M, CAR-T therapy for B-ALL and Lymphoma, 3rd Annual Meeting of the Ukrainian
Professional Society of Paediatriconcology/haematology, Ukraine 7th Apr 2023 (Invited
lecture, oral presentation, web).
Tanaka Y, DIAGNOSTIC DILEMMA BETWEEN PUBIC OSTEOLYSIS AND NEOPLASMS IN OSTEOLYTIC LESION
OF THE PUBIS , 21st European Federation of Internal Medicine, Athens, Greece, March
16th, 2023.
Furukawa Y, Ishii M, Goto A, Kinoshita S, Ando J, Nakauchi H, Ando M, iPSC-derived CD4 T
cell generation and investigation of CD4/CD8 T cell lineage choice, ASH2023, San Diego,
USA, Dec 2023 (Poster presentation) Award.
Kinoshita S, Ishii M, Furukawa Y, Sato S, Ando J, Nakauchi H, Ando M, iPSC-derived dual
antigen receptor T cells targeting GD2 and LMP2 antigens for extranodal NK/T cell
lymphoma, nasal type, ASH2023, San Diego, USA, Dec 2023 (Poster presentation).
Ando M, Ishii M, Furukawa Y,Igarashi KJ, Kinoshita S, Azusawa Y, Terao Y, Ando J,
Nakauchi H, iPSC-derived hypoimmunogenic T cells enriched with tissue resident memory T
cells powerfully attack cervical cancer, ISSCR 2023 Annual Meeting, Boston, USA, June
2023 (oral presentation).
Edahiro Y, Kirito K, Gotoh A, Takenaka K, Sugimoto Y, Komatsu N, Shimoda K, The Impact
of polycythemia vera on daily living, and symptom and treatment perception gaps between
patients and physicians: results of a cross-sectional survey in Japan, EHA 2023 Hybrid
Congress, Frankfurt & virtual, June 8-11, 2023.
三森 徹, Efficiency and safety of treatment with of polatuzumab vedotin, bendamustine, and
rituximab(Pola-BR) for relapsed/refractory diffuse large B-cell lymphoma at
single-center experience, 日本臨床腫瘍学会, 福岡, 2023年3月16日
Sakai K, Nakazawa H, Hirokawa M, Fujishima N, Yonemura Y, Arai S, Harigae H, Matsuda A,
Komatsu N, Tohyama K, Nakao S, Kurokawa M, Mitani K, Ishida F, Impact of time to
response to CsA/PSL in patients with PRCA: from interim analysis of PRCA2016,
第85回日本血液学会学術集会, 東京, 2023年10月13日(金)~15日(日)
Ando M, iPSC-derived dual antigen receptor T cell therapy for EBV-associated lymphomas,
The 7th Tsurui Lymphoma Workshop, 釧路, 2023年2月24日
Suzuki K, Takaku T, Watanabe N, Ochi K, Torii S, Yamada K, Kawamura Y, Shimizu S,
Komatsu N, Ando M , MAPK activation and Drp1 phosphorylation induce AI-detectable
mitochondrial changes in CML cells, 第85回日本血液学会学術集会, 東京, 2023年10月14日
Imanaka R, Katsuoka Y, Uoshima N, Hara S, Ando J, Goto T, Ota S, Yoshimoto G, Matsuoka
A, Hashiba H, Morita T, Tsutsui A, Numata H, Multicenter study of real-world experience
of venetoclax for newly diagnosed AML in Japan (VENUS), 第85回日本血液学会学術集会, 東京,
2023年10月13〜15日(口演)
Shimoda K, Komatsu N, Matsumura I, Ikeda K, Hino M, Hidaka M, Maeda Y, Kondo T, Fujisaki
T, Shoshi K, Azuma K, Fukushima R, Kawashima J, Kosugi H, Phase 3 study of momelotinib
vs ruxolitinib in JAK inhibitor naive myelofibrosis patients in Japan, 第85回日本血液学会学術集会,
東京, 2023年10月13日(金)~15日(日)
Watanabe N, Takaku T, Iriyama N, Iwanaga E, Kimura Y, Ishikawa M, Nakayama H, Sato E,
Tabayashi T, Mitsumori T, Nakazato T, Tokuhira M, Fujita H, Ando M, Hatta Y, Kawaguchi T
, Usefulness of New Risk Prediction Model for VAEs in Japanese Patients with CML Treated
with TKIs in a Practice-Based Stud, The 85th Annual Meeting of the Japanese Society of
Hematology, 東京, 2023年10月14日
Ando J, Furukawa Y, Ishii M, Kinoshita S, Sato S, Tsukune Y, Yasuda H, Takaku T, Hamano
Y, Sasaki M, Ando M, Venetoclax combinations in untreated and R/R AML with single-cell
RNA-seq, TP53-mutated patients, 第85回日本血液学会学術集会, 東京, 2023年10月13 - 15日(口演)
Baba T, Hashimoto Y, Yasuda H, Araki M, Edahiro Y, Morishita S, Ochiai T, Shirane S, Ando J, Komatsu N,
Validation and reliability of current guidelines for the treatment of essential thrombocythemia under real-world
clinical settings in Japan, Hematology, 2022; 27(1): 157-166. doi: 10.1080/16078454.2021.2022848.
De Marchi F, Okuda M, Morishita S, Imai M, Baba T, Horino M, Mori Y, Furuya C, Ogata S, Yang Y, Ando J, Ando M,
Araki M, Komatsu N, Clinical and biological relevance of CREB3L1 in Philadelphia chromosome-negative
myeloproliferative neoplasms, Leukemia research, 2022; 119: 106883. pii: S0145-2126(22)00109-6.
Edahiro Y, Ito T, Gotoh A, Nakamae M, Kimura F, Koike M, Kirito K, Wada H, Usuki K, Tanaka T, Mori T, Wakita S,
Saito TI, Kada A, Saito AM, Shimoda K, Sugimoto Y, Kurokawa T, Tomita A, Hashimoto Y, Akashi K, Matsumura I,
Takenaka K, Komatsu N, Clinical characteristics of Japanese patients with polycythemia vera: results of the
JSH-MPN-R18 study, Int J Hematol, 2022; 116(5): 696-711.
Edahiro Y, Koike M, Nojiri S, Harada Y, Gotoh A, Fujibayashi K, Nishizaki Y, Yanagisawa N, Takaku T, Nitta H,
Tsukune Y, MisawaK, Kobayashi H, Komatsu N, A pilot study examining the efficacy of hochuekkito for improving
quality of life in patients with myeloproliferative neoplasms, Jpn J Clin Oncol, 2022; 52: 880-886.
Edahiro Y, Kurokawa Y, Morishita S, Yamamoto T, Araki M, Komatsu N, Causes of thrombocytosis: A single-center
retrospective study of 1,202 patients, Intern Med, 2022;61(22):3323-3328.
Edahiro Y, Ohishi K, Gotoh A, Takenaka K, Shibayama H, Shimizu T, Usuki K, Shimoda K, Ito M, VanWart SA,
Zagrijtschuk O, Qin A, Kawase H, Miyachi N, Sato T, Komatsu N, Kirito K, Correction to: Efficacy and safety of
ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study,
Int J Hematol, 2022; 116(4): 642-643.
Edahiro Y, Ohishi K, Gotoh A, Takenaka K, Shibayama H, Shimizu T, Usuki K, Shimoda K, Ito M, VanWart SA,
Zagrijtschuk O, Qin A, Kawase H, Miyachi N, Sato T, Komatsu N, Kirito K, Efficacy and safety of ropeginterferon
alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study, Int J Hematol,
2022; 116(2): 215-227.
Furukawa Y, Hamano Y, Shirane S, Kinoshita S, Azusawa Y, Ando J, Nakauchi H, Ando M, Advances in allogeneic
cancer cell therapy and future perspectives on “off-the-shelf” T cell therapy using iPSC technology
and gene editing, Cells, 2022; 11(2): 269.
Furuya C, Hashimoto Y, Morishita S, Inano T, Ochiai T, Shirane S, Edahiro Y, Araki M, Ando M, Komatsu N,
Reevaluation of cardiovascular risk factors for thrombotic events in 580 Japanese patients with essential
thrombocythemia, Journal of Thrombosis and Thrombolysis, 2022; doi: 10.1007/s11239-022-02751-0.
Harada S, Ando M, Ando J, Ishii M, Yamaguchi T, Yamazaki S, Toyota T, Ohara K, Ohtaka M, Nakanishi M, Shin C,
Ota Y, Nakashima K, Ohshima K, Imai C, Nakazawa Y, Nakauchi H, Komatsu N , Dual-antigen targeted iPSC-derived
chimeric antigen receptor-T cell therapy for refractory lymphoma, Molecular therapy : the journal of the
American Society of Gene Therapy, 2022; 30(2): 534-549. doi: 10.1016/j.ymthe.2021.10.006.
Hashimoto Y, Ito T, Gotoh A, Nakamae M, Kimura F, Koike M, Kirito K, Wada H, Usuki K, Tanaka T, Mori T, Wakita
S, Saito TI, Kada A, Saito AM, Shimoda K, Sugimoto Y, Kurokawa T, Tomita A, Edahiro Y, Akashi K, Matsumura I,
Takenaka K, Komatsu N, Clinical characteristics, prognostic factors, and outcomes of patients with essential
thrombocythemia in Japan: the JSH-MPN-R18 study, International Journal of Hematology, 2022; 115(2): 208-221.
Iida S, Izumi T,Komeno T,Terui Y, Chou T, Ikeda T,Berg D,Fukunaga S,Sugiura K,Sasaki M, A phase 2, open-label,
multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed
and/or refractory multiple myeloma, Int J Clin Oncol, 2022; 27(1): 224-233.
Iizuka K, Morishita S, Nishizaki Y, Iizuka Y, Iriyama N, Ochiai T, Yanagisawa N, Yasuda H, Ando J, Gotoh A,
Takei M, Hatta Y, Nakamura H, Nakayama T, Komatsu N, von Willebrand factor activity levels are influenced by
driver mutation status in polycythemia vera and essential thrombocythemia patients with well-controlled platelet
counts, Eur J Haematol, 2022; 109(6): 779-786.
Iizuka-Honma H, Mitsumori T, Yoshikawa S, Takizawa H, Noguchi M, Factors Associated With Survival in Patients
With End-of-Life Hematological Malignancies Who Received Chemotherapy: A Retrospective Single-Institution Study,
Am J Hosp Palliat Care,2022; 10499091221142502.
Iizuka-Honma H, Mitsumori T, Yoshikawa S, Takizawa H, Noguchi M, Prognostic Value of Palliative Prognostic Index
for Hospitalized Patients With End-of-Life Hematologic Malignancies in a Japanese University Hospital, JCO Oncol
Pract, 2022; 18(1): e108-e116. doi: 10.1200/OP.21.00243.
Inano T, Araki M, Morishita S, Imai M, Kihara Y, Okuda M, Yang Y, Ito M, Osaga S, Mano H, Edahiro Y, Ochiai T,
Misawa K, Fukuda Y, Ando J, Komatsu N, Author Correction: Cell-autonomous megakaryopoiesis associated with
polyclonal hematopoiesis in triple-negative essential thrombocythemia, Scientifc Reports, 2022; 12(1): 1115.
Kitamura H, Kubota Y, Tomimasu R, Akashi M, Mori T, Mine Y, Ando J, Murayama SY, Kimura S, Miyahara M,
Non-valvular Infective Endocarditis Caused by Sarocladium kiliense in an Immunocompromised Patient with Aplastic
Anemia, Internal medicine, 2022; 61(8): 1279-1283. doi: 10.2169/internalmedicine.7536-21.
Komatsu N, Hashimoto Y, Baba T, Otsuka M, Akimoto T, Fernandez J, Safety and efficacy of anagrelide in Japanese
post-marketing surveillance, with subgroup analyses on the effect of previous cytoreductive therapies, age, and
starting dose, Int J Hematol, 2022; 116(4): 570-578.
Liu C, Imai M, Edahiro Y, Mano S, Takei H, Nudejima M, Kurose A, Morishita S, Ando M, Tsuneda S, Araki M,
Komatsu N, Establishment of isogenic induced pluripotent stem cells with or without pathogenic mutation for
understanding the pathogenesis of myeloproliferative neoplasms, Experimental Hematology, 2022; 118: 12-20. doi:
10.1016/j.exphem.2022.11.005.
Marumo A, Wakita S, Morita K, Oh I, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A,
Usuki K, Uoshima N, Kobayashi Y, Kawata E, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Hagihara M, Uchiyama H,
Kubota Y, Kimura S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Date K, Fujiwara Y,
Terada K, Yui S, Arai K, Kitano T, Miyata M, Ohashi K, Kanda Y, Yamaguchi H, NPM1-mutation-based measurable
residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical
predictor of the prognosis of acute myeloid leukemia, International journal of hematology, 2022; 116(2):
199-214. doi: 10.1007/s12185-022-03328-6.
Mesa R, Komatsu N, Gill H, Jin J, Lee SE, Hou HA, Sato T, Qin A, Urbanski R, Shih W, Zagrijtschuk O, Zimmerman
C, Verstovsek S, MPN-545 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide as Second Line Therapy in
Essential Thrombocythemia, Clin Lymphoma Myeloma Leuk, 2022; 22Suppl2: S342.
Mori Y, Araki M, Morishita S, Imai M, Edahiro Y, Ito M, Ochiai T, Shirane S, Hashimoto Y, Yasuda H, Ando J, Ando
M, Komatsu N, Clinical features of acquired erythrocytosis: Low levels of serum erythropoietin in a subset of
non-neoplastic erythrocytosis patients, Cancer Med, 2022; 12(2):1079-1089. doi: 10.1002/cam4.4958.
Morishita S, Hashimoto Y, Furuya C, Edahiro Y, Ochiai T, Shirane S, Inano T, Yasuda H, Ando M, Araki M, Komatsu
N, Non-driver gene mutation analysis in a large cohort of polycythemia vera and essential thrombocythemia, Eur J
Haeato, 2022; 110(2): 131-136. doi: 10.1111/ejh.13882.
Nishiyama-Fujita Y, Nakazato T, Iriyama N, Tokuhira M, Ishikawa M, Sato E, Takaku T, Sugimoto K, Fujita H,
Fujioka I, Tsuchiya S, Kimura Y, Iwanaga E, Komatsu N, Asou N, Kizaki M, Hatta Y, Kawaguchi T, Outcomes of
adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase
inhibitors, Annals of Medicine, 2022; 54(1): 1244-1254.
Ogama Y, Kumagai Y, Komatsu N, Araki M, Masubuchi N, Akiyoshi H, Matsuura T, Kirisako H, Kyoya A, Nomura F,
Ohira Y, Yokokawa T, Yamamoto Y, Phase 1 Clinical Trial of PPMX-T003, a Novel Human Monoclonal Antibody Specific
for Transferrin Receptor 1, to Evaluate Its Safety, Pharmacokinetics, and Pharmacodynamics, Clin Pharmacol Drug
Dev, 2022; doi: 10.1002/cpdd.1216. Online ahead of print.
Pecquet C, Papadopoulos N, Balligand T, Chachoua I, Tisserand A, Vertenoeil G, Nédélec A,
Vertommen D, Roy A, Marty C, Nivarthi H, Defour JP, El-Khoury M, Hug E, Majoros A, Xu E, Zagrijtschuk O, Fertig
TE, Marta DS, Gisslinger H, Gisslinger B, Schalling M, Casetti IC, Rumi E, Pietra D, Cavalloni C, Arcaini L,
Cazzola M, Komatsu N, Kihara Y, Sunami Y, Edahiro Y, Araki M, Lesyk R, Buxhofer-Ausch V, Heibl S, Pasquier F,
Plo I, Vainchenker W, Kralovics R, Constantinescu SN, Secreted Mutant Calreticulins As Rogue Cytokines in
Myeloproliferative Neoplasms, Blood, 2022; 2022016846. doi: 10.1182/blood.2022016846.
Suzuki M, Koyama D, Ikeda S, Sukegawa M, Teshirogi M, MisawaK, Tsunoda S, Serum IgG and lymphocyte counts are
useful for the early detection of infection in patients receiving bendamustine-rituximab therapy, J Clin Exp
Hematop, 2022; 62(2): 91-98.
Tanaka Y, Takeda R, Fukushima T, Mikami K, Tsuchiya S, Tamura M, Adachi K, Umemoto T, Asada S, Watanabe N,
Morishita S, Imai M, Nagata M, Araki M, Takizawa H, Fukuyama T, Lamagna C, Masuda ES, Ito R, Goyama S, Komatsu
N, Takaku T, Kitamura T, Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors, Nat Commun,
2022; 13(1): 271.
Tsuyama N, Noguchi M, Asaka R, Sakata S, Baba S, Izumi H, Takeuchi K, Hodgkinoid histiocytosis: an atypical
nodal CD30 and S100-positive histiocytosis with eosinophilia, Histopathology, 2022; 81(3): 371-379. doi:
10.1111/his.14718.
Ugawa M, Kawamura Y, Toda K, Teranishi K, Morita H, Adachi H, Tamoto R, Nomaru H, Nakagawa K, Sugimoto K,
Borisova E, An Y, Konishi Y, Tabata S, Morishita S, Imai M, Takaku T, Araki M, Komatsu N, Hayashi Y, Sato I,
Horisaki R, Noji H, Ota S, In silico-labeled ghost cytometry, Elife, 2022; 10: e67660.
Verstovsek S, Komatsu N, Gill H, Jin J, Lee SE, Hou HA, Sato T, Qin A, Urbanski R, Shih W, Zagrijtschuk O,
Zimmerman C, Mesa RA, SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line
therapy in essential thrombocythemia, Future Oncol, 2022; 18(27): 2999-3009.
Wakita S, Sakaguchi M, Oh I, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K,
Ueki T, Uoshima N, Kobayashi Y, Kawata E, Tajika K, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Kayamori K,
Hagihara M, Uchiyama H, Uchida N, Kubota Y, Kimura S, Nagoshi H, Ichinohe T, Kurosawa S, Motomura S, Hashimoto
A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Marumo A, Omori I, Fujiwara Y, Terada K, Yui S, Arai K, Kitano
T, Miyata M, Kurosawa A, Mizoguchi A, Komatsu N, Fukuda T, Ohashi K, Kanda Y, Inokuchi K, Yamaguchi H,
Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia, Blood Advances, 2022; 6(1): 238-247.
doi: 10.1182/bloodadvances.2021004292.
Watanabe N, Takaku T, Fujioka I, Tsuchiya S, Ando M, Bosutinib-induced late-onset severe liver injury preceded
by eosinophilia, Ann Hematol, 2022; 101(10): 2257-2262.
Watanabe N, Takaku T, Tsukune Y, Yasuda H, Ochiai T, Yamada K, Nakazawa H, Hotta S, Nishimaki T, Takagi H,
Takahashi K, Komatsu N, Ando M, Bosutinib-induced lung injury: a report of two cases and literature review, Int
J Hematol, 2022; 115(6): 902-905.
Watari H, Kageyama H, Masubuchi N, Nakajima H, Onodera K, Focia PJ, Oshiro T, Matsui T, Kodera Y, Ogawa T,
Yokoyama T, Hirayama M, Hori K, Freymann DM, Imai M, Komatsu N, Araki M, Tanaka Y, Sakai R, A marine
sponge-derived lectin reveals hidden pathway for thrombopoietin receptor activation, Nat Commun, 2022; 13(1):
7262.
Yamamoto K, Shinagawa A, DiNardo CD, Pratz KW, Ishizawa K, Miyamoto T, Komatsu N, Nakashima Y, Yoshida C,
Fukuhara N, Usuki K, Yamauchi T, Asada N, Asou N, Choi I, Miyazaki Y, Honda H, Okubo S, Kurokawa M, Zhou Y, Zha
J, Potluri J, Matsumura I, Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid
leukemia ineligible for intensive chemotherapy, Jpn J Clin Oncol, 2022; 52(1): 29-38.
Yasuda H, Furukawa Y, Nishioka K, Sasaki M, Tsukune Y, Shirane S, Hattori N, Ando M, Komatsu N, Vitamin B6
deficiency as a cause of polyneuropathy in POEMS syndrome: rapid recovery with supplementation in two cases,
Hematology, 2022; 27: 463-468.
Yasuda H, Hatano T, Honda T, Tsutsui M, Hattori N, Ando M, Komatsu N, Vitamin B6 Deficiency Anemia Attributed
to Levodopa/Carbidopa Intestinal Gel Therapy forParkinson's Disease: A Diagnostic Pitfall
for Myelodysplastic Syndrome with Ring Sideroblasts, Intern Med, 2022; 61(24): 3719-3722.
Yasuda H, Komatsu N, Ando J, Ando M, Hodgkin Lymphoma on Hemodialysis: A Review of Treatment and
Recommendations, Clinical lymphoma, myeloma & leukemia, 2022; 22(11): 805-811. Pii: S2152-2650(22)00226-9.
Yasuda H, Tomizawa Y, Harada S, Sasaki M, Komatsu N, Ando J, Hattori N, Ando M,
Anti-myelin-associated-glycoprotein neuropathy successfully treated with tirabrutinib, Heliyon, 2022; 8(10):
e10928. doi: 10.1016/j.heliyon.2022.e10928.
Yokomizo T, Ideue T, Morino-Koga S, Cheng Yong Tham, Sato T, Takeda N, Kubota Y, Kurokawa M, Komatsu N, Ogawa M,
Araki K, Osato M, Suda T, Independent origins of fetal liver haematopoietic stem and progenitor cells, Nature,
2022; 609(7928): 779-784.
Yoshida C, Kondo T, Ito T, Kizaki M, Yamamoto K, Miyamoto T, Morita Y, Eto T, Katsuoka Y, Takezako N, Uoshima N,
Imada K, Ando J, Komeno T, Mori A, Ishikawa Y, Satake A, Watanabe J, Kawakami Y, Morita T, Taneike I, Nakayama
M, Duan Y, Guijarro B, Delgado A, Llamas C, Kiyoi H, Real-world treatment patterns and clinical outcomes in
patients with AML in Japan who were ineligible for first-line intensive chemotherapy, International journal of
hematology, 2022; 116(1): 89-101. doi: 10.1007/s12185-022-03334-8.
英文症例報告
Hasui H, Iseki T, Ueno Y, Kamiyama D, Miyamoto N, Kijima C, Hira K, Komatsu N, Hattori N, Recurrent and Multiple
Intracerebral Hemorrhages in Polycythemia Vera Secondary to Myelofibrosis: A Case Report and Literature Review,
Case
Rep Neurol, 2022; 14(2): 274-280.
Higo R, Kojima M, Itoha S, Noguchi M, Izumi H, Takeuchi K, Primary diffuse large B-cell lymphoma of the Larynx,
Auris Nasus Larynx, 2022; 14: 50.
Iizuka-Honma H, Takizawa H, Mitsumori T, Okura H, Ishii H, Noguchi M, Refractory Primary Vitreoretinal Lymphoma
Involving the Spinal Cord with a Temporary Complete Response to Tirabrutinib, Intern Med, 2022; 62(3): 459-463.
doi:
10.2169/internalmedicine.9591-22.
Inano T, Yasuda H,Tsukune Y, Tsutsui M, Wali N, Saeki H, Kajino K, Hino O, Masaki Y, Komatsu N, Abnormal
Exacerbation of Moderately Differentiated Gastric Adenocarcinoma in a Patient with TAFRO Syndrome: An Impaired
Tumor
Immunity?, Case Rep Oncol, 2022; 15: 7-11.
Misawa K, Yasuda H, Matsuda H, Hara M, Ochiai T, Koyama D, Takano H, Iwao N, Koike M, Adult paroxysmal cold
hemoglobinuria following mRNA COVID-19 vaccination, eJHaem, 2022; 3: 992–995.
Misawa K, Yasuda H, Matsuda H, Hara M, Ochiai T, Koyama D, Takano H, Iwao N, Koike M, Development of Acute Adult
T-cell Leukemia Following PD-1 Blockade Therapy for Lung Cancer, Intern Med, 2022; 61(22): 3421-3424.
Sekiguchi Y, Ishikawa A, Kanda H, Kawamura M, Tomita S, Noguchi M, A Case of EBER Positive Angioimmunoblastic
T-cell
Lymphoma Combined with Myxofibrosarcoma of the Pleura, Tokai J Exp Clin Med, 2022; 47(1): 1-8.
Shirane S, Najima Y, Fukushima K, Sekiya N, Funata N, Kishida Y, Nagata A, Yamada Y, Konishi T, Kaito S,
Kurosawa S,
Yoshifuji K, Uchida T, Inamoto K, Shingai N, Toya T, Igarashi A, Shimizu H, Kobayashi T, Kakihana K, Sakamaki H,
Ohashi K, Horiguchi S, Hishima T, Doki N, Central nervous system mucormycosis in a patient with hematological
malignancy: A case report and review of the literature, J infect Chemother, 2022; 28(12): 1658-1662. doi:
10.1016/j.jiac.2022.08.003.
Uchimura A, Yasuda H, Ando J, Ota Y, Sasaki M, Takaku T,Tsukune Y, Tsutsui M, Edahiro Y, Watanabe N, Ochiai T,
Komatsu N, Ando M, Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab
Vedotin, Case Rep Oncol, 2022; 15: 263-266.
Watanabe N, Kitahara H, Honda T, Iwasaki H, Iwao N, Komatsu N, Koike M, High incidence of disseminated
intravascular
coagulation and acute cerebral infarction in acute myeloid leukemia with cup-like nuclei, J Clin Exp Hematop,
2022;
62(4): 249-252.
Yasuda H, Ando J, Yoshida S, Ota Y, Komatsu N, Ando M, Diffuse large B-cell lymphoma with adrenal involvement
presenting as other iatrogenic immunodeficiency-associated lymphoproliferative disorders: sustained remission
with
methotrexate termination alone in two cases, Internal Medicine, 2022; doi: 10.2169/internalmedicine.0130-22.
Yasuda H, Hoshino Y, Ando J, Miyachi M, Osawa M, Hattori N, Ando M, Vitamin B6 deficiency polyneuropathy and
dermatitis, The American Journal of Medicine, 2022; S0002-9343(22): 00717-3.
国際学会発表
Ando M, Single-institution experience in unfit AML treated with Venetoclax, Educational Course on Acute Myeloid
Leukemia(AML), MD Anderson Cancer Center Preceptorship in Japan, Tokyo, Aug 20-21 2022.
Kaito Y, Sugimoto E, Nakamura F, Tsukune Y, Sasaki M, Yui S, Yamaguchi H, Goyama S, Nannya Y, Mitani K, Tamura
H, Imai Y, DNAM-1/Tigit/CD155/CD112 Axis Is a Novel Target of NK-Cell Therapy in Acute Myeloid Leukemia, 64th
American Society of Hematology Annual Meeting & Exposition, Orlando, USA, December 10-13 2022.
Kirito K, Edahiro Y, Ohishi K, Gotoh A, Takenaka K, Shibayama H, Shimizu T, Usuki K, Shimoda K, Ito M, VanWart
S, Zagrijtschuk O, Qin A, Kawase H, Miyachi N, Sato T, Komatsu N, Phase 2, open-label, multicenter, single-arm
study investigating the efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia
vera , EHA2022 Congress, Vienna(Hybrid), June 10 2022.
Marumo A, Wakita S, Morita K, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K,
Ueki T, Uoshima N, Kobayashi Y, Kawata E, Nakayama K, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Hagihara M,
Uchiyama H, Uchida N, Kubota Y, Kimura S, Nagoshi H, Ichinohe T, Kurosawa S, Motomura S, Hashimoto A, Muto H,
Sato E, Ogata M, Mitsuhashi K, Ando J, Tashiro H, Sakaguchi M, Yui S, Arai K, Kitano T, Miyata M, Fukuda T,
Kanda Y, Yamaguchi H, Mutational Analysis of DNMT3A Improves the Prognostic Stratification Using NPM1/FLT3-ITD
Genotypes in Patients with Acute Myeloid Leukemia, The 64th American Society of Hematology Annual Meeting, New
Orleans, December 10-13 2022. Poster Session #158686
Sasaki M, Suzuki K, Abe Y, Ito S, Nishiwaki K, Handa H, Chou T, Soeda J, Mori I, Shinozaki T, Takezako N,
Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable proteasome
inhibitor-based therapy in patients with relapsed/refractory multiple myeloma, 27th European Hematology
Association 2022 annual meeting, Vinena Austria +hybrid, Jun 15-17 2022.
Takezako N, Suzuki K, Abe Y, Ito S, Nishiwaki K, Handa H, Chou T, Soeda J, Mori I, Shinozaki T, Sasaki M,
Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable proteasome
inhibitor-based therapy in patients with relapsed/refractory multiple myeloma, 19th International Myeloma
Society Annual Meeting, LA California, Aug 25-27 2022.
Uchimura A, Efficient use of blinatumomab for a patient with recurrent Philadelphia chromosome-positive acute
lymphoblastic leukemia after multiple allogenic hematopoietic-cell transplantations, EBMT 7th International
Transplantation Course, Bercelona, September 3 2022.
和文総説
枝廣 陽子, 日本における骨髄増殖性腫瘍のreal world data, 臨床血液, 2022; 63(9): 1083-1091.
Baba T, Masubuchi N, Morishita S, Shioiri K, Kihara Y, Ando M, Araki M, Komatsu N, Endogenous expression of
MPLW515L showed a weak oncogenic capacity in UT-7/TPO cells, 第84回日本血液学会学術集会, 福岡, 2022年10月14日(金)~16日(日)
Edahiro Y, Hsiao H-H, Tanaka H, Ikeda T, Fujii M, Ono K, Okubo S, Potluri J, Yeh S-P, Safety and tolerability of
navitoclax plus ruxolitinib in patients with myelofibrosis, 第84回日本血液学会学術集会, 福岡, 2022年10月15日
Furukawa Y, Ando J, Ishii M, Kinoshita S, Ando M, A novel extranodal NK/T-cell lymphoma, nasal type cell line,
ENKL-J1, 第84回日本血液学会学術集会, 福岡, 2022年10月15日
Furuya C, Hashimoto Y, Morishita S, Ando M, Komatsu N,
日本人のMPL変異陽性本態性血小板血症の臨床的特徴についてーMPL変異はJAK2V617F変異と同様に血栓症のリスク因子であるー, 第84回日本血液学会学術集会, 福岡, 2022年10月14日
Furuya C, Hashimoto Y, Morishita S, Ando M, Komatsu N,
本態性血小板血症における,心血管リスク因子と血栓症発症との関連性についてー高トリグリセリド血症は血栓症の強いリスク因子であるー, 第84回日本血液学会学術集会, 福岡, 2022年10月14日
Honda A, Toyama K, Oyama Y, Matsuda K, Mizuno H, Saito A, Katayama Y, Komatsu N, Kurokawa M, Prognostic factors
of idiopathic hypereosinophilic syndrome: A nationwide survey in Japan, 第84回日本血液学会学術集会, 福岡,
2022年10月14日(金)~16日(日)
Iwakiri M, Nagata Y, Sheng J, Marumo A, Sakaguchi M, Arai K, Kitano T, Miyata M, Wakita S, Kuroda J, Nagao Y,
Tadokoro J, Uchiyama H, Kimura S, Motomura S, Sato E, Ogata M, Mitsuhashi K, Ando J, Kanda J, Kawata E, Doki N,
Mori S, Uoshima N, Kako S, Kanda Y, Shono K, Satake A, Yamaguchi H, The clinical and genetic features of
Japanese de novo AML with IDH1/2 and SRSF2 mutations., 第84回日本血液学会学術集会, 福岡, 2022年10月16日
Morishita S, De Marchi F, Okuda M, Imai M, Baba T, Mori Y, Furuya C, Ogata S, Yang Y, Ando J, Ando M, Araki M,
Komatsu N, Clinical relevance of CREB3L1 expression in Ph-negative MPN, 第84回日本血液学会学術集会, 福岡,
2022年10月14日(金)~16日(日)
Sheng J, Nagata Y, Marumo A, Sakaguchi M, Arai K, Kitano T, Miyata M, Wakita S, Kuroda J, Nagao Y, Tadokoro J,
Uchiyama H, Kimura S, Motomura S, Sato E, Ogata M, Mitsuhashi K, Ando J, Kanda J, Kawata E, Doki N, Mori S,
Uoshima N, Kako S, Kanda Y, Shono K, Satake A, Yamaguchi H, Clinical impact of IDH1/2 mutations in AML patients
treated with Venetoclax, 第84回日本血液学会学術集会, 福岡, 2022年10月14日
Shirane S, Hamano Y, Uchimura A, Mori Y, Tsutsui M, Ando M, 脾照射の影響が示唆された同種造血幹細胞移植後の肝類洞閉塞症候群3例,
第84回日本血液学会学術集会, 福岡, 2022年10月14日
Cervantes F, Ross DM, Radinoff A, Palandri F, Myasnikov A, Vannucchi AM, Zachee P, Gisslinger H, Komatsu N,
Foltz L, Mannelli F, Passamonti F, Gilotti G, Sadek I, Tiwari R, Zor E, Al-Ali HK, Efficacy and safety of a
novel dosing strategy for ruxolitinib
in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study, Leukemia, 2021 Dec;
35(12): 3455-3465.
Edahiro Y, Yasuda H, Gotoh A, Morishita S, Suzuki T, Takeda J, Ando J, Tsutsui M, Itakura A, Komatsu N,
Interferon therapy for pregnant patients with essential thrombocythemia in Japan, Int J Hematol, 2021 Jan;
113(1): 106-111.
Harada S, Ando M, Ando J, Ishii M, Yamaguchi T, Yamazaki S, Toyota T, Ohara K, Ohtaka M, Nakanishi M, Shin C,
Ota Y, Nakashima K, Ohshima K, Imai C, Nakazawa Y, Nakauchi H, Komatsu N, Dual-antigen targeted iPSC-derived
chimeric antigen receptor-T cell
therapy for refractory lymphoma, Molecular Therapy, in press, 2021.
Ikeda S, Tsunoda S, Koyama D, Suzuki M, Sukegawa M, Misawa K, Hojo H, Zhu X, Utano K, Ohta M, Femoral marrow MRI
is a non-invasive, non-irradiated and useful tool for detecting bone marrow involvement in non-Hodgkin lymphoma,
J Clin Exp Hematop, 2021
Jun; 61(2): 78-84.
Inano T, Araki M, Morishita S, Imai M, Kihara Y, Okuda M, Yang Y, Ito M, Osaga S, Mano M, Edahiro Y, Ochiai T,
Misawa K, Fukuda Y, Ando J, Komatsu N, Cell-autonomous megakaryopoiesis associated with polyclonal hematopoiesis
in triple-negative essential
thrombocythemia, Scientific Reports, 2021 Sep; 11(1): 17702.
Ishii M, Ando J, Yamazaki S, Toyota T, Ohara K, Furukawa Y, Suehara Y, Nakanishi M, Nakashima K, Ohshima K,
Nakauchi H, Ando M, iPSC-derived neoantigen-specific cytotoxic T-lymphocyte therapy for Ewing sarcoma, Cancer
Immunology Research, 2021; 9(10):
1175-1186.
Kinoshita S, Ando M, Ando J, Ishii M, Furukawa Y, Tomita O, Shirane S, hito Kishita Y, Yatsuka Y, Eguchi H,
Okazaki Y, Komatsu N, Trigenic ADH5 / ALDH2 / ADGRV1 mutations in myelodysplasia with Usher syndrome, Heliyon,
2021; 7(8): e07804.
Komatsu N, Arita K, Mitsui H, Nemoto T, Hanaki K, Efficacy and safety of ferric citrate hydrate compared with
sodium ferrous citrate in Japanese patients with iron deficiency anemia: a randomized, double-blind, phase 3
non-inferiority study, Int J Hematol,
2021 Jul; 114(1): 8-17.
Morishita S, Yasuda H, Yamawaki S, Kawaji H, Itoh M, Edahiro Y, Imai M, Kogo Y, Tsuneda S, Ohsaka A, Hayashizaki
Y, Ito M, Araki M, Komatsu N, CREB3L1 overexpression as a potential diagnostic marker of Philadelphia
chromosome-negative myeloproliferative
neoplasms, Cancer Sci, 2021 Feb; 112(2): 884-892.
Morishita S, Ochiai T, Misawa K, Osaga S, Inano T, Fukuda Y, Edahiro Y, Ohsaka A, Araki M, Komatsu N, Clinical
impacts of the mutational spectrum in Japanese patients with primary myelofibrosis, eron therapy for pregnant
patients with essential thrombocythemia
in Japan, Int J Hematol, 2021 Apr; 113(4): 500-507.
Ochi Y, Yoshida K, Huang YJ, Kuo MC, Nannya Y, Sasaki K, Mitani K, Hosoya N, Hiramoto N, Ishikawa T, Branford S,
Shanmuganathan N, Ohyashiki K, Takahashi N, Takaku T, Tsuchiya S, Kanemura N, Nakamura N, Ueda Y, Yoshihara S,
Bera R, Shiozawa Y, Zhao L,
Takeda J, Watatani Y, Okuda R, Makishima H, Shiraishi Y, Chiba K, Tanaka H, Sanada M, Takaori-Kondo A, Miyano S,
Ogawa S, Shih LY, Clonal evolution and clinical implications of genetic abnormalities in blastic transformation
of chronic myeloid leukaemia,
Nat Commun, 2021 May 14; 12(1): 2833.
Ohara K, Kinoshita S, Ando J, Azusawa Y, Ishii M, Harada S, Mitsuishi Y, Asao T, Tajima K, Yamamoto T, Takahashi
F, Komatsu N, Takahashi K, Ando M, SCLC-J1, a novel small cell lung cancer cell line, Biochem Biophys Rep, 2021
Jul; 27: 101089.
Tanaka Y, Takeda R, Fukushima T, Mikami K, Tsuchiya S, Tamura M, Adachi K, Uemoto T, Asada S, Watanabe N,
Morishita S, Imai M, Nagata M, Araki Mi, Takizawa H, Fukuyama T, Lamagna C, Masuda E, Ito R, Goyama S, Komatsu
N, Takaku T, Kitamura T, Eliminating
chronic myeloid leukemia stem cells by IRAK 1/4 inhibitors, Nature Communications, in press, 2021
Ugawa M, Kawamura Y, Toda K, Teranishi K, Morita H, Adachi H, Tamoto R, Nomaru H, Nakagawa K, Sugimoto K,
Borisova E, An Y, Konishi Y, Tabata S, Morishita S, Imai M, Takaku T, Araki M, Komatsu N, Hayashi Y, Sato I,
Horisaki R, Noji H, Ota S, In silico-labeled
ghost cytometry Elife, 2021 Dec; 10: e67660.
Watanabe N, Gao S, Wu Z, Batchu S, Kajigaya S, Diamond C, Alemu L, Raffo DQ, Hoffmann P, Stone D, Ombrello AK,
Young NS. Analysis of deficiency of adenosine deaminase 2 pathogenesis based on single-cell RNA sequencing of
monocytes, J Leukoc Biol. 2021
Sep; 110(3): 409-424.
Yamauchi T, Yoshida C, Usuki K, Takada S, Matsumura I, Dobashi N, Miyazaki Y, Miyamoto T, Iida H, Asou N, Kuroda
J, Ichikawa S, Komatsu N, Mendes W, Honda H, Okubo S, Kurokawa M, Jiang Q, Wei A, Ishizawa K, Venetoclax plus
low-dose cytarabine in Japanese
patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy, Jpn J Clin Oncol, 2021
Aug; 51(9): 1372-1382.
Yasui H, Kobayashi M, Sato K, Kondoh K, Ishida T, Kaito Y, Tamura H, Handa H, Tsukune Y, Sasaki M, Komatsu N,
Tanaka N, Tanaka J, Kizaki M, Kawamata T, Circulating cell-free DNA in the peripheral blood plasma of patients
is an informative biomarker for
multiple myeloma relapse, Int J Clin Oncol, 2021 Nov; 26(11): 2142-2150.
英文総説
Yasuda H, Yasuda M, Komatsu N, Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: A
comprehensive review, Cancer Sci, 2021 Jul; 112(7): 2607-2624.
英文著書
Ando M, Kinoshita S, Furukawa Y, Ando J, Nakauchi H, Brenner MK: Advances in stem cell biology, volume 12,
Molecular Players in iPSC Technology, Elsevier, 2021, Chapter 3, Improving the safety of iPSC-derived T cell
therapy, 95-115.
英文症例報告
Ando J, Ueno Y, Yasuda H, Ando M, Edahiro Y, Honda T, Takanashi M, Taniguchi D, Hattori N, Komatsu N,
Radiation-Induced Myopathy Developing in a Hodgkin Lymphoma Patient: An Autopsy Case with Systemic Muscle
Sampling, Case Rep Oncol, 2021 Mar; 14(1):
338-342.
Edahiro Y, Takaku T, Suzuki M, Fukuda Y, Harada S, Kinoshita S, Inano T, Shirane S, Hamano Y, Kondo A, Komatsu
N, Intravascular large B-cell lymphoma as a recurrence of primary central nervous system lymphoma after
chemotherapy: A case report, Leuk Res
Rep, 2021 May; 15: 100249.
Fukumura Y, Taniguchi G, Koyanagi A, Horiuchi Y, Ochiai T, Tabe Y, Sano K, Maimaitiaili Y, Otsuji N, Ashizawa K,
Yao T, A Case of Untreated Myeloid Sarcoma of the Pancreas Head Region: Diagnostic Process of AML Subtyping in
an Autoptic Case, Case Rep
Pathol, 2021
Furukawa Y, Ando J, Ando M, Kinoshita S, Edahiro Y, Furuta T, Ohshima K, Komatsu N, Long-term spontaneous
regression of Stage IV diffuse large B-cell lymphoma, J Clin Exp Hematop, 2021 Sep; 61(3): 168-172.
Furukawa Y, Ando M, Azusawa Y, Kinoshita S, Harada S, Ochiai T, Honda T, Sugimoto K, Tabe Y, Komatsu N, Ando J,
Persistent immune thrombocytopaenic purpura associated with SARS-CoV-2 infection, EJHaem, 2021 May; 2(3),
530-533.
Harada S, Ando J, Ando M, Azusawa Y, Ochiai T, Hashimoto Y, Hirasawa Y, Komatsu N, Sarcoma-like appearance but
pathologic Hodgkin lymphoma, Int J Hematol, 2021 Jul; 114(1): 1-2.
Harada S, Ando J, Ando M, Nitta H, Inano T, Hirasawa Y, Furukawa Y, Kinoshita S, Kondo A, Ohshima K, Komatsu N,
High-grade Primary Central Nervous System Lymphomatoid Granulomatosis: Successful Rituximab Monotherapy, Intern
Med, 2021 Dec; 60(23): 3795-3799.
Haraguchi M, Harada N, Watanabe J, Yoshikawa H, Shirai Y, Komura M, Koyama M, Ito J, Tsukune Y, Horimoto Y,
Hayashi T, Nagaoka T, Uekusa T, Takahashi K, Disseminated nontuberculous mycobacteriosis and fungemia after
second delivery in a patient with MonoMAC
syndrome/GATA2 mutation: a case report, BMC Infect Dis, 2021; 21: 502.
Iizuka H, Harada S, Iwao N, Koike M, Noguchi M, Primary Skeletal Muscle Peripheral T-cell Lymphoma: An Autopsy
Case Report and Review of the Literature,Internal medicine, 2021; 60(20): 3309-3315.
Iizuka H, Mori Y, Iwao N, Koike M, Noguchi M, Hemophagocytic lymphohistiocytosis associated with Epstein-Barr
virus-positive diffuse large B-cell lymphoma, NOS of bone marrow-liver-spleen type: an autopsy case report,
Journal of clinical and experimental
hematopathology, 2021 Jun; 61(2): 102-108.
Iizuka H, Mori Y, Fukuda Y, Iwao N, Koike M, Noguchi M, Two autopsy cases of pulmonary leukemic infiltration
mimicking severe pneumonia in patients with acute myeloid leukemia, Leukemia Research Reports, 2021; 16: 100269.
Kinoshita S, Ando J, Ando M, Komatsu N, Primary Lymphoma of the Pericardium, Intern Med, 2021 Dec; 60(24):
4005-4006.
Mori T, Abe H, Yoshida M, Tsukune Y, Yahata Y, Takaku T, Ando J, Ando M, Torii S, Sasaki M, Immunohistochemical
detection of aflatoxin in lesions of aflatoxin-producing Aspergillus flavus infection, Medical Mycology Journal,
2021; 62(3): 47-52.
Takahashi M, Makino S, Iizuka H, Noguchi M, Yoshida K, Chronic active Epstein-Barr virus associated secondary
hemophagocytic lymphohistiocytosis in pregnancy: a case report, lBMC Pregnancy Childbirth, 2021; 21: 681.
Sano M, Iseki T, Sasaki M, Tsukune Y, Yasuda H, Kanazawa K, Arakawa A, Yokoyama K, Komatsu N, Hattori N,
Nishioka K, Improvement in the Symptoms and VEGF Levels after Resection of an Extrame Dullary Spinal Tumor and
Additional Chemotherapy in a Patient
with Multiple Myeloma Complicated with POEMS Syndrome, Intern Med, 2021; 60: 3625-3630.
Sekiguchi Y, Nishitani M, Takizawa H, Iizuka H, Mitsumori T, Noguchi M, Sawada T, Yoshikawa S, Okubo T, Okubo M,
Yoshikawa S, A Case of CCR4-Positive, Localized Primary ATLL of the Bone, Ann Case Report, 2021; 6: 650.
Shirane S, Watanabe D, Sekiya N, Horiguchi S, Najima Y, Paraplegia via hematogenous dissemination of
Cunninghamella elegans (mucormycosis) after hematopoietic stem cell transplantation, Int J Infect Dis, 2021 Dec;
113: 210-212.
Takahashi M, Makino S, Iizuka H, Noguchi M, Yoshida K, Chronic active Epstein-Barr virus associated secondary
hemophagocytic lymphohistiocytosis in pregnancy: a case report, lBMC Pregnancy Childbirth, 2021; 21: 681.
Yamashita Y, Takahashi Y, Tsunemi T, Shirane S, Nakazato-Taniguchi T, Taniguchi D, Takanashi M, Sasaki M,
Komatsu N, Hattori N, Systemic sclerosis precedes POEMS syndrome, Can J Neurol Sci, 2021 May; 48(3): 446-449.
Yasuda H, Morishita S, Mori Y, Tsukune Y, Inano T, Harada S, Komatsu N, JAK2/CALR/SF3B1 triple-mutated
myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis evolving to myelofibrosis
and SF3B1 single-mutated acute myeloid
leukemia: evidence of a pre-JAK2 clone, Leuk Res, 2021 Jan; 100: 106496.
Yasuda H, Tsukune Y, Tadaaki Inano, Yosuke Mori, Yasunori Ota, Komatsu N, Successful long-term ibrutinib
treatment in a hemodialysis patient with leukemic non-nodal mantle cell lymphoma, Clin Lymphoma Myeloma Leuk,
2021 Feb; 21(2): e176-e178.
Yasuda H, Mori Y, Chiba A, Bai J, Murayama G, Matsushita Y, Miyake S, Komatsu N, Resolution of one-year
persisting COVID-19 pneumonia and development of immune thrombocytopenia in a follicular lymphoma patient with
preceding rituximab maintenance therapy:
a follow-up report and literature review of cases with prolonged infections, Clin Lymphoma Myeloma Leuk, 2021
Oct; 21(10): e810-e816.
国際学会発表
Ando M, Ando J, Ishii M, Honda T, Kinoshita S, Furukawa Y, Masuda A, Kitade M, Terao Y and Nakauchi H,
iPSC-derived "off-the-shelf" CTL therapy for cervical cancers.
ISSCR International Symposium Tokyo 2021, Tokyo, Japan, 29th Oct, 2021 (oral presentation)
Ishii M, Ando J, Toyota T, Ohara K, Nakauchi H, Ando M, iPSC-derived neoantigen-specific cytotoxic T lymphocyte
therapy for Ewing sarcoma, ISSCR 2021, Virtual (poster), 21 June - 26 June, 2021
Mesa RA, Komatsu N, Gill H, Jin J, Lee SE, Hou HA, Sato T, Qin A, Urbanski R, Shih W, Zagrijtschuk O, Zimmerman
C, Verstovsek S, Surpass-ET Trial: A Phase 3, Open-Label, Multicenter, Randomized, Active-Controlled Study to
Assess Pharmacokinetics and Compare
the EJcacy, Safety, and Tolerability of P1101 Vs Anagrelide As Second Line Therapy for Essential Thrombocythemia
63nd ASH, December 11, 2021
Sekiguchi Y, Iizuka H, Takizawa H, Mitsumori Tet, al, Use of Ibrutinib in 10 Patients with Treatment-Naïve
or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in Real-World Clinical Practice
-A Report from a Single Medical Institution,
癌と化学療法, 2021 Jul; 48(7): 921-926.
Sekiguchi Y, Nishitani M, Takizawa H, Iizuka H, Mitsumori T, et al, Low-Risk Essential Thrombocythemia Who
Presented with Recurrent Episodes of Cerebral Hemorrhage during Pregnancy and Developed Cerebral Infarction
during Puerperium, 癌と化学療法, 2021 May;
48(5): 725-730.
Hiromi Watari, Hiromu Kageyama, Hiroya Nakajia, Kako Onodera, Nami Masubuchi, Takumi Oshiro, Takashi Matui,
Yoshio Kodera, Tomohisa Ogawa, Makoto Hirayama, Kanji Hori, Takeshi Yokoyama, Norio Komatsu, Marito Araki,
Yoshikazu Tanaka, Ryuichi Sakai, Marine
sponge lectin reveals the mechanism of sugar-chain mediated activation of MPL , 第83回日本血液学会学術集会, Web開催,
2021年9月23日(木・祝)~25日(土)
Kaoko Sakai, Hideyuki Nakazawa, Makoto Hirokawa, Naohito Fujishima, Yuji Yonemura, Shunya Arai, Hideo Harigae,
Akira Matsuda, Norio Komatsu, Kaoru Tohyama, Shinji Nakao, Mineo Kurokawa, Kinuko Mitani, Fumihiro Ishida, One
third of the patients with acquired
chronic PRCA show macrocytic anemia: data from PRCA2016, 第83回日本血液学会学術集会, Web開催, 2021年9月23日(木・祝)~25日(土)
Kazuya Sugimoto, Miki Ando, Jun Ando, Midori Ishii, Yoko Azusawa, Yoshiki Furukawa, Shintaro Kinoshita, Tadahiro
Honda, Sakiko Harada, Hiromitsu Nakauchi, Norio Komatsu, Development of iPSC-derived Tax-specific CTL therapy
for adult T-cell leukemia/lymphoma,
第83回日本血液学会学術集会, Web開催, 2021年9月23日(木・祝)~25日(土)
Norio Komatsu, Terumi Baba, Manami Otsuka, Takafumi Akimoto, Jovelle Fernandez, Safety and efficacy of
anagrelide from post-marketing surveillance data in Japan, 第83回日本血液学会学術集会, Web開催, 2021年9月23日(木・祝)~25日(土)
Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T, Sugimoto K.J, Fujita H, Kimura Y, Fujioka I,
Asou N, Komatsu N, Kizaki M, Hatta Y, Kawaguchi T. The EUTOS long-term survival score predicts disease-specific
mortality and molecular responses
among patients with chronic myeloid leukemia in a practice-based cohort. Cancer Med 2020;9(23):8931-8939.
Shuhei Kurosawa , Noriko Doki, Yasushi Senoo, Yuya Kishida, Akihito Nagata, Yuta Yamada, Tatsuya Konishi,
Satoshi Kaito, Kota Yoshifuji, Naoki Matsuyama, Shuichi Shirane, Tomoyuki Uchida, Kyoko Inamoto, Takashi Toya,
Aiko Igarashi, Yuho Najima, Hideharu
Muto, Takeshi Kobayashi, Kazuhiko Kakihana, Hisashi Sakamaki, Kazuteru Ohashi. Bone turnover markers as an aid
to monitor osteoporosis following allogeneic hematopoietic stem cell transplantation. Annals of hematology 2020;
59(16):1947-1956.
Morishita S, Yasuda H, Yamawaki S, Kawaji H, Itoh M, Edahiro Y, Imai M, Kogo Y, Tsuneda S, Ohsaka A, Hayashizaki
Y, Ito M, Araki M, Komatsu N. CREB3L1 overexpression as a potential diagnostic marker of Philadelphia
chromosome-negative myeloproliferative
neoplasms. Cancer Sci 2020.
Masuda A, Isobe Y, Sugimoto K, Yoshimori M, Arai A, Komatsu N. Efficient recruitment of c-FLIPL to the
death-inducing signaling complex leads to Fas resistance in natural killer-cell lymphoma. Cancer Sci 2020;
111(3):807-816.
Masubuchi N, Araki M, Yang Y, Hayashi E, Imai M, Edahiro Y, Hironaka Y, Mizukami Y, Kihara Y, Takei H, Nudejima
M, Koike M, Ohsaka A, Komatsu N. Mutant calreticulin interacts with MPL in the secretion pathway for activation
on the cell surface. Leukemia
2020;34(2):499-509.
Makoto Murata, Ritsuro Suzuki, Tetsuya Nishida, Shuichi Shirane, Yutaka Shimazu, Yosuke Minami, Takehiko Mori,
Noriko Doki, Yoshinobu Kanda, Naoyuki Uchida, Masatsugu Tanaka, Jun Ishikawa, Kazuto Togitani, Takahiro Fukuda,
Tatsuo Ichinohe , Yoshiko Atsuta,
Tokiko Nagamura-Inoue, Hitoshi Kiyoi. Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential
Thrombocythemia and Post-polycythemia Vera Myelofibrosis. Internal Medicine 2020; 28(11): 2394-2405,
Komatsu N, Jun G, Yonezu T, Ohashi Y. Real-world, retrospective study evaluating thromboembolic events,
associated risk factors, and health-care resource utilization in Japanese patients with polycythemia vera. Int J
Hematol 2020; 112(2):176-184.
Ishibashi M, Takahashi R, Tsubota A, Sasaki M, Handa H, Imai Y, Tanaka N, Tsukune Y, Tanosaki S, Ito S, Asayama
T, Sunakawa M, Kaito Y, Kuribayashi-Hamada Y, Onodera A, Moriya K, Komatsu N, Tanaka J, Odajima T, Sugimori H,
Inokuchi K, Tamura H. SLAMF3-mediated
signaling via ERK pathway activation promotes aggressive phenotypic behaviors in multiple myeloma. Mol Cancer
Res 2020; 18: 632-43.
Honda T, Ando M, Ando J, Ishii M, Sakiyama Y, Ohara K, Toyota T, Ohtaka M, Masuda A, Terao Y, Nakanishi M,
Nakauchi H, Komatsu N. Sustainable tumor suppressive effect of iPSC-derived rejuvenated T cells targeting
cervical cancers. Mol Cancer Res 2020;
18: 632-43.
Edahiro Y, Yasuda H, Gotoh A, Morishita S, Suzuki T, Takeda J, Ando J, Tsutsui M, Itakura A, Komatsu N.
Interferon therapy for pregnant patients with essential thrombocythemia in Japan. Int J Hematol 2020; in press
Edahiro Y, Yasuda H, Ando K, Komatsu N. Self-limiting pregnancy-associated pure red cell aplasia developing in
two consecutive pregnancies: case report and literature review. Int J Hematol 2020;111(4):579-584.
Araki M, Komatsu N. The role of calreticulin mutations in myeloproliferative neoplasms. Int J Hematol
2020;111(2):200-205.
Ando M, Ando J, Yamazaki S, Ishii M, Sakiyama Y, Harada S, Honda T, Yamaguchi T, Nojima M, Ohshima K, Nakauchi
H, Komatsu N. Long-term eradication of extranodal Natural killer /T-cell lymphoma, nasal type, by induced
pluripotent stem cell-derived Epstein-Barr
virus-specific rejuvenated T cells in vivo. Haematologica 2020;105(3):796-807.
Ando M, Ando J, Honda T, Ishii M, Nakauchi H, Komatsu N. iPSC-derived rejuvenated T cell therapy for extranodal
NK/T-cell lymphoma, nasal type. Juntendo Medical Journal 2020; 66: 200-205,
Ando J, Ueno Y, Yasuda H, Ando M, Edahiro Y, Honda T, Takanashi M, Taniguchi D, Hattori N, Komatsu N. Radiation
induced myopathy developing in a Hodgkin lymphoma patient: an autopsy case with systemic muscle sampling. Case
Reports in Oncology 2020; in
press
Ando J, Ngo MC, Ando M, Leen A, Rooney CM. Identification of protective T-cell antigens for smallpox vaccines.
Cytotherapy 2020;22(11):642-652,
Yasuda H, Tsukune Y, Watanabe N, Sugimoto K, Uchimura A, Tateyama M, Miyashita Y, Ochi Y, Komatsu N. Persistent
COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for
Follicular Lymphoma. Clin Lymphoma
Myeloma Leuk, 2020; 20(11):774-776
Yasuda H, Tsukune Y, Inano T, Mori Y, Ota Y, Komatsu N. Successful Long-Term Ibrutinib Treatment in a
Hemodialysis Patient With Leukemic Nonnodal Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk 2020.
Yamashita Y, Takahashi Y, Tsunemi T, Shirane S, Nakazato-Taniguchi T, Taniguchi D, Takanashi M, Sasaki M,
Komatsu N, Hattori N. Systemic Sclerosis Precedes POEMS Syndrome. Can J Neurol Sci 2020:1-4.
Semba R, Horimoto Y, Arakawa A, Edahiro Y, Takaku T, Iijima K, Saito M, Difficulty Diagnosing a Brain Tumor
during Clinical Maintenance of a Complete Response to anti-HER2 Treatments for Metastatic Breast Cancer: A Case
Report. Case Rep Oncol. 2020; 23;13(3):1311-1316
Morishita S, Yasuda H, Yamawaki S, Kawaji H, Itoh M, Edahiro Y, Imai M, Kogo Y, Tsuneda S, Ohsaka A, Hayashizaki
Y, Araki M, Komatsu N. 3082CREB3L1Overexpression Can Reliably Discriminate Ph-MPNs from Reactive Cases. 62nd
ASH, Dec7.
Kihara Y, Araki M, Imai M, Mori Y, Mei H, Ogata S, Yoshikawa S, Taguchi T, Masubuchi N, Mabuchi Y, Yang Y,
Fukuda Y, Morishita S, Suzuki T, Domae N, Shimonaka M, Akazawa C, Ohsaka A, Komatsu N. 716Therapeutic Potential
of an Antibody Targeting the Cleaved
Form of Mutant Calreticulin in Myeloproliferative Neoplasms. 62nd ASH, 7 Dec.
Inano T, Araki M, Morishita S, Imai M, Kihara Y, Okuda M, Ito M, Osaga S, Yang Y, Edahiro Y, Ochiai T, Misawa K,
Fukuda Y, Ohsaka A, Komatsu N. 2177 Concomitant Occurrence of Polyclonal Hematopoiesis and Cell-Autonomous
Megakaryopoiesis in Triple-Negative
Essential Thrombocythemia. 62nd ASH, 6 Dec.
Yokomizo T, Ideue T, Araki K, Kurokawa M, Komatsu N, Osato M, Suda T. In vivo tracing of hematopoietic stem and
progenitor cell formation in the mouse embryo. 第82回日本血液学会学術集会, Web, 10月10日~11月8日.
Yasuda S, Aoyama S, Yoshimoto R, Watanabe D, Yamamoto K, Fujiwara T, Edahiro Y, Imai M, Araki M, Komatsu N,
Miura O, Kawamata N. Overexpression of MPL causes ruxolitinib-resistance in MPN with CALR frame-shift mutations.
第82回日本血液学会学術集会, Web, 10月10日~11月8日.
Tsuchiya S, Takaku T, Fujioka I, Watanabe N, Iriyama N, Sato E, Nakazato T, Kimura Y, Sugimoto K, Fujita H,
Ishikawa M, Iwanaga E, Hatta Y, Asou N, Kizaki M, Komatsu N, Tokuhira M, Kawaguchi T. Risk factors and
management of pleural effusion in the dasatinib
treated Japanese CML patients. 第82回日本血液学会学術集会, Web, 10月10日~11月8日.
Tokuhira M, Kimura Y, Iriyama N, Tsuchiya S, Takaku T, Fujita Y, Nakazato T, Sato E, Sugimoto K, Fujita H,
Ishikawa M, Fujioka I, Hatta Y, Komatsu N, Asou N, Kizaki M, Iwanaga E, Kawaguchi T. C linical results of
dasatinib treatment in elderly patients
with newly diagnosed CML-CP. 第82回日本血液学会学術集会, Web, 10月10日~11月8日.
Tokuhira M, Kimura Y, Fujita Y, Nakazato T, Ishikawa M, Sugimoto K, Iriyama N, Tsuchiya S, Takaku T, Fujita H,
Sato E, Fujioka I, Asou N, Hatta Y, Komatsu N, Kizaki M, Iwanaga E, Kawaguchi T. Clinical results of nilotinib
treatment in elderly patients
with newly diagnosed CML-CP. 第82回日本血液学会学術集会, Web, 10月10日~11月8日.
Takaku T, Tsuchiya S, Endo D, Tsutui M, Nitta H, Kajimoto K, Amano A, Komatsu N. The development of primary
cardiac large B cell lymphoma during the treatment for CML. 第82回日本血液学会学術集会, Web, 10月10日~11月8日.
Shioiri K, Araki M, Kitazawa S, Masubuchi N, Morishita S, Imai M, Ohsaka A, Komatsu N. Analysis of behavior of
erythropoietin receptor on the cell surface in JAK2 mutant cells. 第82回日本血液学会学術集会, Web, 10月10日~11月8日.
Shibayama H, Itagaki M, Handa H, Yokoyama, Sawamura M, Kosugi S, Minauchi K, Nakamura D, Shimazu Y, Sugiura I,
Fuchida S, Iino M, Shimizu T, Moriuchi Y, Toyama K, Mitani K, Tsukune Y, Kada A, Tamura H, Abe M, Iwasaki H,
Kuroda J, Takamatsu H, Sunami K,
Kizaki M, Ishida T, Saito T, Matsumura I, Akashi K, Iida S. Patient demographics in a prospective observational
study of plasma cell neoplasms in Japan. 第82回日本血液学会学術集会, Web, 10月10日~11月8日.
Sato E, Aritaka N, Kitahara H, Masuda A, Ochiai T, Kinoshita S, Ota Y, Hirano T, Komatsu N. Bortezomib therapy
of Waldenstrom's macroglobulinemia with simultaneous IgM and IgG paraproteinemia. 第82回日本血液学会学術集会, Web,
10月10日~11月8日.
Ochiai T, Sato E, Sugimoto K, Tsunoda A, Fukai T, Komatsu N. Successful treatment Sezary syndrome with
bexarotene monotherapy. 第82回日本血液学会学術集会, Web, 10月10日~11月8日.
Moriyama M, Akahane D, Moriya S, Yamada A, Imai M, Araki M, Komatsu N, Miyazawa K, Gotoh A. Targeting ER stress
enhances inhibitory effect of ruxolitinib in mutated-CALR transfected cells. 第82回日本血液学会学術集会, Web, 10月10日~11月8日.
Morishita S, Yasuda H, Yamawaki S, Kawaji H, Itoh M, Edahiro Y, Imai M, Kogo Y, Tsuneda S, Ohsaka A, Hayashizaki
Y, Araki M, Komatsu N. CREB3L1 overexpression as a novel diagnostic marker of myeloproliferative neoplasms.
第82回日本血液学会学術集会, Web, 10月10日~11月8日.
Misawa K, Furukawa Y, Fujioka I, Iwao N, Komatsu N, Koike M. Characteristics of the elderly patients with AML in
the Juntendo Shizuoka Hospital. 第82回日本血液学会学術集会, Web, 10月10日~11月8日.
Kinoshita R, Ishibashi M, Handa H, Sasaki M, Komatsu N, Imai Y, Ito S, Tanaka N, Tanaka J, Isoda A, Matsumoto M,
Tanosaki S, Sunakawa M, Asayama T, Inokuchi K, Tamura H. FGFR3 overexpression was not associated with poor
survival in t(4;14)+ multiple myeloma
patients. 第82回日本血液学会学術集会, Web, 10月10日~11月8日.
Kihara Y, Araki M, Imai M, Fukuda Y, Mori Y, Taguchi T, Masubuchi N, Mabuchi Y, Yang Y, Mizukami Y, Morishita S,
Akazawa C, Ohsaka A, Komatsu N. Therapeutic potential of myeloproliferative neoplasms by antibody targeting
mutant calreticulin. 第82回日本血液学会学術集会,
Web, 10月10日~11月8日.
Fukuda Y, Takaku T, Furuya C, Shirane S, Edahiro Y, Hamano Y, Komatsu N. Two cases of R-CHOP therapy combined
with eltrombopag for treatment DLBCL complicated with AA. 第82回日本血液学会学術集会, Web, 10月10日~11月8日.
Edahiro Y, Takaku T, Fukuda Y, Harada S, Kinoshita S, Inano T, Shirane S, Hamano Y, Komatsu N. The development
of IVLBCL after the treatment for PNCSL. 第82回日本血液学会学術集会, Web, 10月10日~11月8日.
特別講演・招待講演
安藤純. 第1部 キムリア治療における治療提供可能施設間の連携. KYMRIAH Network Meeting in Tokyo, 2020
安藤純. キムリア Up to date 〜最新の知見を踏まえて〜. KYMRIAH Web Seminar from Tokyo, 2020
小松則夫. 骨髄増殖性腫瘍の治療最前線~本態性血小板血症を中心に~. 甲信越 MPN e-Conference WEB 11月6日.
2019年
英文原著
Yokomizo T, Watanabe N, Umemoto T, Matsuo J, Harai R, Kihara Y, Nakamura E, Tada N, Sato T, Takaku T, Shimono A,
Takizawa H, Nakagata N, Mori S, Kurokawa M, Tenen D G, Osato M, Suda T, Komatsu N. Hlf marks the developmental
pathway for hematopoietic stem
cells but not for erythro-myeloid progenitors. J Exp Med 2019;216(7):1599-1614.
Yasuda H, Tsutsui M, Ando J, Inano T, Noguchi M, Yahata Y, Tanaka M, Tsukune Y, Masuda A, Shirane S, Misawa K,
Gotoh A, Sato E, Aritaka N, Sekiguchi Y, Sugimoto K, Komatsu N. Vitamin B6 deficiency is prevalent in primary
and secondary myelofibrosis patients.
Int J Hematol 2019;110(5):543-549.
Tsukune Y, Sasaki M, Komatsu N. Reactivation of Hepatitis B Virus in Patients with Multiple Myeloma. Cancers
(Basel) 2019;11(11):1819.
Tsukune Y, Sasaki M, Isoda A, Ando J, Koike M, Matsumoto M, Sawamura M, Tamura H, Handa H, Imai Y, Yahata Y,
Komatsu N. Safety of lenalidomide, dexamethasone, and cyclophosphamide in elderly Japanese patients with
relapsed and refractory multiple myeloma:
results of phase 1 study. International Journal of Myeloma 2019;9(2):1-6.
Sugiyama M, Ueno Y, Kamo H, Edahiro Y, Miyamoto N, Yamashiro K, Tanaka R, Shimo Y, Komatsu N, Hattori N.
Specific mechanisms of subarachnoid hemorrhage accompanied by ischemic stroke in essential thrombocythemia: two
case reports and a literature review.
J Neurol 2019;266(8):1869-1878.
Maekawa T, Kato S, Kawamura T, Takada K, Sone T, Ogata H, Saito K, Izumi T, Nagao S, Takano K, Okada Y, Tachi N,
Teramoto M, Horiuchi T, Hikota-Saga R, Endo-Umeda K, Uno S, Osawa Y, Kobayashi A, Kobayashi S, Sato K, Hashimoto
M, Suzu S, Usuki K, Morishita
S, Araki M, Makishima M, Komatsu N, Kimura F. Increased SLAMF7 high monocytes in myelofibrosis patients
harboring JAK2V617F provide a therapeutic target of elotuzumab. Blood 2019;134(10):814-825.
Kimura K, Tabe Y, Ai T, Takehara I, Fukuda H, Takahashi H, Naito T, Komatsu N, Uchihashi K, Ohsaka A. A novel
automated image analysis system using deep convolutional neural networks can assist to differentiate MDS and AA.
Sci Rep 2019;9(1):13385.
Ishikawa M, Iriyama N, Tokuhira M, Takaku T, Sato E, Sugimoto K-J, Nakazato T, Fujita H, Kimura Y, Fujioka I,
Komatsu N, Asou N, Kizaki M, Hatta Y, Kawaguchi T. Potential role for second-generation tyrosine kinase
inhibitors in patients with chronic myeloid
leukemia harboring additional clonal chromosome abnormalities: A retrospective CML Cooperative Study Group
analysis. Oncol Rep 2019;42(6):2836-2843.
Iriyama N, Tokuhira M, Sato E, Sugimoto K-J, Takaku T, Ishikawa M, Nakazato T, Fujita H, Kimura Y, Fujioka I,
Asou N, Komatsu N, Kizaki M, Hatta Y, Kawaguchi T. Smoking influences the outcomes of patients receiving
tyrosine kinase inhibitors for chronic
myeloid leukemia in the chronic phase: A retrospective analysis. Hematol Oncol 2019;37(3):323-325.
Inano T, Araki M, Morishita S, Imai M, Yasuda H, Nitta H, Ito M, Edahiro Y, Ochiai T, Misawa K, Fukuda Y, Ohsaka
A, Komatsu N. JAK2 exon 12 mutation in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and
thrombocytosis: Not an exclusive
mutation to polycythaemia vera. Br J Haematol 2019;187(1):e27-e31.
Hayashi Y, Harada Y, Kagiyama Y, Nishikawa S, Ding Y, Imagawa J, Shingai N, Kato N, Kitaura J, Hokaiwado S,
Maemoto Y, Ito A, Matsui H, Kitabayashi I, Iwama A, Komatsu N, Kitamura T, Harada H. NUP98-HBO1-fusion generates
phenotypically and genetically
relevant chronic myelomonocytic leukemia pathogenesis. Blood Adv 2019;3(7):1047-1060.
Hatsumi N, Miyawaki S, Yamauchi T, Takeshita A, Komatsu N, Usui N, Arai Y, Ishida F, Morii T, Kano Y, Ogura M,
Machida S, Nishii K, Honda S, Ohnishi K, Naoe T. Phase II study of FLAGM (fludarabine + high-dose cytarabine +
granulocyte colony-stimulating
factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia. Int J Hematol 2019;109(4):418-425.
Gerds A T, Tauchi T, Ritchie E, Deininger M, Jamieson C, Mesa R, Heaney M, Komatsu N, Minami H, Su Y, Shaik N,
Zhang X, DiRienzo C, Zeremski M, Chan G, Talpaz M. Corrigendum to "Phase 1/2 trial of glasdegib in patients
with primary or secondary myelofibrosis
previously treated with ruxolitinib" [Leukemia Res. 79 (2019) 38-44]. Leuk Res 2019;81:10
Gerds A T, Tauchi T, Ritchie E, Deininger M, Jamieson C, Mesa R, Heaney M, Komatsu N, Minami H, Su Y, Shaik N,
Zhang X, DiRienzo C, Zeremski M, Chan G, Talpaz M. Phase 1/2 trial of glasdegib in patients with primary or
secondary myelofibrosis previously
treated with ruxolitinib. Leuk Res 2019;79:38-44.
Fukuda Y, Araki M, Yamamoto K, Morishita S, Inano T, Misawa K, Ochiai T, Edahiro Y, Imai M, Yasuda H, Gotoh A,
Ohsaka A, Komatsu N. Evidence for prevention of renal dysfunction associated with primary myelofibrosis by
cytoreductive therapy. Haematologica
2019;104(11):e506-e509.
Edahiro Y, Araki M, Inano T, Ito M, Morishita S, Misawa K, Fukuda Y, Imai M, Ohsaka A, Komatsu N. Clinical and
molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential
thrombocythemia in Japan. Eur
J Haematol 2019;102(6):516-520.
Araki M, Yang Y, Imai M, Mizukami Y, Kihara Y, Sunami Y, Masubuchi N, Edahiro Y, Hironaka Y, Osaga S, Ohsaka A,
Komatsu N. Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation. Leukemia
2019;33(1):122-131.
Yamasaki S, Nitta H, Kondo E, Uchida N, Miyazaki T, Ishiyama K, Kiyota M, Matsuoka H, Ichinohe T, Fukuda T,
Atsuta Y, Suzumiya J, Suzuki R. Effect of allogeneic hematopoietic cell transplantation for patients with
T-prolymphocytic leukemia: a retrospective
study from the Adult Lymphoma Working Group of the Japan Society for hematopoietic cell transplantation. Ann
Hematol 2019;98(9):2213-2220.
Kurosawa S, Sekiya N, Doki N, Yaguchi T, Kishida Y, Nagata A, Yamada Y, Konishi T, Kaito S, Yoshifuji K, Shirane
S, Uchida T, Inamoto K, Toya T, Igarashi A, Najima Y, Muto H, Kobayashi T, Kakihana K, Sakamaki H, Ohashi K. The
emergence of rare nocardiosis
following allogeneic hematopoietic stem cell transplantation in the era of molecular taxonomy. Int J Infect Dis
2019;89:154-162.
Konishi T, Doki N, Kishida Y, Nagata A, Yamada Y, Kaito S, Kurosawa S, Yoshifuji K, Shirane S, Uchida T, Inamoto
K, Toya T, Igarashi A, Najima Y, Kobayashi T, Kakihana K, Sakamaki H, Ohash K. Geriatric nutritional risk index
(GNRI) just before allogeneic
hematopoietic stem cell transplantation predicts transplant outcomes in patients older than 50 years with acute
myeloid leukemia in complete remission. Ann Hematol 2019;98(7):1799-1801.
De Marchi F, Araki M, Komatsu N. Molecular features, prognosis, and novel treatment options for pediatric acute
megakaryoblastic leukemia. Expert Rev Hematol 2019;12(5):285-293.
Tsutsui M, Yasuda H, Ota Y, Komatsu N. Splenic Marginal Zone Lymphoma with Prominent Myelofibrosis Mimicking
Triple-Negative Primary Myelofibrosis. Case Rep Oncol 2019;12(3):834-837.
Mori T, Watanabe N, Kitahara H, Iwao N, Koike M, Komatsu N. Acquired Factor VIII Inhibitor in a Patient of
Rheumatoid Arthritis on Tumor Necrosis Factor Inhibitor Therapy. Indian J Hematol Blood Transfus
2019;35(1):192-193.
Morishita S, Ochiai T, Misawa K, Inano T, Fukuda Y, Kurokawa Y, Edahiro Y, Araki M, Ohsaka A, Komatsu N.
Mutations in epigenetic and splicing related genes among japanese overt and prefibrotic primary myelofibrosis
using target sequencing. The 10th JSH
INTERNATIONAL SYMPOSIUM 2019 in Ise-Shima, 鳥羽国際ホテル, May 17.
Kato S, Maekawa T, Ogata K, Osawa Y, Nagao S, Takano K, Okada Y, Tachi N, Teramoto M, Kawamura T, Horiuchi T,
Kobayashi A, Kobayashi S, Sato K, Hashimoto M, Suzu S, Usuki K, Morishita S, Araki M, Komatsu N, Kimura F.
SLAMF7high CD16negative Monocytes
Increase in Peripheral Blood of Patients with Myelofibrosis in Correlation with JAK2V617F Mutation. 24th
Congress of the European Hematology Association, Amsterdam, June 13-16.
Ishibashi M, Kinoshita R, Inokuchi K, Handa H, Sasaki M, Komatsu N, Imai Y, Hiroike N, Tanaka J, Tanosaki S, Ito
S, Sunakawa M, Asayama T, Kuribayashi-hamada Y, Morita R, Tamura H. Serum Soluble CD86, Still a Prognostic
Factor in the Novel Agent Era in
Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression. American Society of
Hematology, Orange County Convention Center (OCCC), Orlando, FL, USA, December 9.
枝廣陽子, 竹井拓, ChangLiu, 橳島麻衣, 森下総司, 大坂顯通, 荒木真理人, 小松則夫. The impact of allelic burden of JAK2V617F on human
hematopoietic cell differentiation. 第29回日本サイトメトリー学会学術集会, 順天堂大学, 5月26日.
枝廣陽子. Clinical and molecular features of patients with prefibrotic/early primary myelofibrosis in a Japanese
cohort. 第81回日本血液学会学術集会, 東京国際フォーラム, 10月12日.
Araki M, Yang Y, Imai M, Mizukami Y, Kihara Y, Sunami Y, Masubuchi N, Edahiro Y, Hironaka Y, Osaga S, Ohsaka A,
Komatsu N. Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation.
Leukemia. 2018. [Epub ahead of print]
Watanabe N, Kitahara H, Iwao N, Ohta Y, Koike M, Komatsu N. Retroperitoneal relapse in an older patient with
multiple myeloma during pomalidomide and dexamethasone treatment. Geriatr Gerontol Int. 2018;18(6):977-9.
Tokuhira M, Kimura Y, Sugimoto K, Nakazato T, Ishikawa M, Fujioka I, Takaku T, Iriyama N, Sato E, Fujita H,
Hatta Y, Komatsu N, Asou N, Kizaki M, Kawaguchi T. Efficacy and safety of nilotinib therapy in patients with
newly diagnosed chronic myeloid leukemia
in the chronic phase. Med Oncol. 2018;35(3):38.
Takei H, Edahiro Y, Mano S, Masubuchi N, Mizukami Y, Imai M, Morishita S, Misawa K, Ochiai T, Tsuneda S, Endo H,
Nakamura S, Eto K, Ohsaka A, Araki M, Komatsu N. Skewed megakaryopoiesis in human induced pluripotent stem
cell-derived haematopoietic progenitor
cells harbouring calreticulin mutations. Br J Haematol. 2018;181(6):791-802.
Takaku T, Iriyama N, Mitsumori T, Sato E, Gotoh A, Kirito K, Noguchi M, Koike M, Sakamoto J, Oba K, Komatsu N.
Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1
Transcript Decline for Achievement of
Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo
Yamanashi Cooperative Study Group. Oncology. 2018;94(2):85-91.
Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Fujioka I, Asou N,
Komatsu N, Kizaki M, Hatta Y, Kawaguchi T. Introduction of second-generation tyrosine kinase inhibitors may
reduce the prognostic impact of high-risk
patients, according to the European treatment and outcome study (EUTOS) score. Leuk Lymphoma.
2018;59(5):1105-12.
Oritani K, Ohishi K, Okamoto S, Kirito K, Komatsu N, Tauchi T, Handa H, Saito S, Takenaka K, Shimoda K, Okada H,
Amagasaki T, Wakase S, Shimozuma K, Akashi K. Effect of ruxolitinib therapy on the quality-of-life of Japanese
patients with myelofibrosis.
Curr Med Res Opin. 2018;34(3):531-7.
Ochiai T, Yasuda H, Araki M, Misawa K, Morishita S, Nudejima M, Hironaka Y, Shirane S, Edahiro Y, Gotoh A,
Ohsaka A, Komatsu N. The 2014 BCSH criteria and the 2016 WHO criteria for essential thrombocythemia: A
comparison in a large-scale cohort. Eur J
Haematol. 2018;100(6):544-9.
Nitta H, Gotoh A, Tanaka M, Sekiguchi Y, Ota Y, Noguchi M, Komatsu N. Pleural effusion at diagnosis predicts
extremely poor outcomes in patients with diffuse large B-cell lymphoma harbouring MYC rearrangement. Br J
Haematol. 2018. [Epub ahead of print]
Nakazato T, Iriyama N, Tokuhira M, Ishikawa M, Sato E, Takaku T, Sugimoto KJ, Fujita H, Fujioka I, Kimura Y,
Aisa Y, Iwanaga E, Asou N, Kizaki M, Hatta Y, Komatsu N, Kawaguchi T. Incidence and outcome of second
malignancies in patients with chronic myeloid
leukemia during treatment with tyrosine kinase inhibitors. Med Oncol. 2018;35(7):99.
Nakamura A, Misawa S, Chonan M, Kawakami T, Horii T, Komatsu N, Ohsaka A. Efficacy of PCR-based open reading
frame typing assay for outbreak investigation of metallo-beta-lactamase-producing Pseudomonas aeruginosa in
hematology unit. J Infect Chemother.
2018. [Epub ahead of print]
Misawa K, Yasuda H, Araki M, Ochiai T, Morishita S, Shirane S, Edahiro Y, Gotoh A, Ohsaka A, Komatsu N.
Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with
myeloproliferative neoplasms. Int J Hematol.
2018;107(6):673-80.
Kirito K, Okamoto S, Ohishi K, Tauchi T, Handa H, Saito S, Takenaka K, Shimoda K, Oritani K, Akashi K, Okada H,
Amagasaki T, Suzuki K, Yonezu T, Komatsu N. Evaluation of the dose and efficacy of ruxolitinib in Japanese
patients with myelofibrosis. Int
J Hematol. 2018;107(1):92-7.
Inokuchi K, Nakayama K, Tauchi T, Takaku T, Yokose N, Yamaguchi H, Kumagai T, Komatsu N, Ohyashiki K.
Therapeutic effects of tyrosine kinase inhibitors and subtypes of BCR-ABL1 transcripts in Japanese chronic
myeloid leukemia patients with three-way chromosomal
translocations. Leuk Res. 2018;65:74-9.
Fujioka I, Takaku T, Iriyama N, Tokuhira M, Kimura Y, Sato E, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H,
Asou N, Kizaki M, Hatta Y, Komatsu N, Kawaguchi T. Features of vascular adverse events in Japanese patients with
chronic myeloid leukemia treated
with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database. Ann Hematol.
2018. [Epub ahead of print]
Asakura K, Azechi T, Sasano H, Matsui H, Hanaki H, Miyazaki M, Takata T, Sekine M, Takaku T, Ochiai T, Komatsu
N, Shibayama K, Katayama Y, Yahara K. Rapid and easy detection of low-level resistance to vancomycin in
methicillin-resistant Staphylococcus
aureus by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. PLoS One.
2018;13(3):e0194212.
Ishibashi M, Soeda S, Sasaki M, Handa H, Imai Y, Tanaka N, Tanosaki S, Ito S, Odajima T, Sugimori H, Asayama T,
Sunakawa M, Kaito Y, Kinoshita R, Kuribayashi Y, Onodera A, Moriya K, Tanaka J, Tsukune Y, Komatsu N, Inokuchi
K, Tamura H. Clinical impact
of serum soluble SLAMF7 in multiple myeloma. Oncotarget. 2018;9(78): 34784-34793.
Sakamoto K, Katayama R, Asaka R, Sakata S, Baba S, Nakasone H, Koike S, Tsuyama N, Dobashi A, Sasaki M,
Ichinohasama R, Takakuwa E, Yamazaki R, Takizawa J, Maeda T, Narita M, Izutsu K, Kanda Y, Ohshima K, Takeuchi K.
Recurrent 8q24 rearrangement in blastic
plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug
response. Leukemia. 2018 Dec;32(12):2590-2603.
英文症例報告
Edahiro Y, Ando J, Suzuki T, Fukumura Y, Masuda A, Sakayori S, Takeda J, Maruyama Y, Makino S, Itakura A,
Komatsu N. Multiple Placental Infarcts in a Pregnant Woman with Essential Thrombocythemia: A Case Report. Intern
Med. 2018.
Yasuda H, Tsutsui M, Ota Y, Tanaka M, Komatsu N. Indolent T-lymphoblastic proliferation concomitant with acinic
cell carcinoma mimicking T-lymphoblastic lymphoma: case report and literature review. Histopathology.
2018;72(5):862-6.
Yamamoto T, Kamijo A, Nakazawa T, Nakajima K, Kirito K, Komatsu N, Masuyama K. A Very Rare Case of
Hypereosinophilic Syndrome Secondary to Natural Killer/T-Cell Lymphoma. Case Rep Otolaryngol. 2018;2018:5965029.
Watanabe N, Gotoh A, Shirane S, Hamano Y, Hirai Y, Shimizu M, Nakamura A, Matsumoto K, Morita K, Mori T, Ohsaka
A, Komatsu N. Breakthrough Exophiala dermatitidis infection during prophylactic administration of micafungin
during second umbilical cord blood
transplantation after graft failure. Transpl Infect Dis. 2018;20(2):e12833.
海外学会発表
Araki M, Masubuchi N, Hayashi E, Yang Y, Imai M, Kihara Y, Mizukami Y, Hironaka Y, Edahiro Y, Ohsaka A, Komatsu
N. Boarding on the secretary pathway is required for the oncogenic property of mutant calreticulin. 23rd
Congress of the European Hematology
Association. Stockholm, Sweden. June, 2018.
Edahiro Y, Mano S, Takei H, Li L, Morishita S, Gotoh A, Tsuneda S, Ohsaka A, Araki M, Komatsu N. Copy number of
JAK2V617F modulates human hematopoietic cell differentiation. 8th International Conference on Myeloproliferative
Neoplasms; 2018 15-May; SAGGART(DUBLIN),
IRELAND.
Nitta H, Gotoh A, Tanaka M, Ochiai T, Ota Y, Komatsu N. The Presence of Pleural Effusion at Diagnosis Predicts
Poor Outcomes in Diffuse Large B-Cell Lymphoma Patients with MYC-Rearrangement or Double Protein Expression.
59th Annual Meeting of the American
Society of Hematology and Exposition; 2017 11-Dec; Atlanta, USA.
Takaku T, Iriyama N, Mitsumori T, Sato E, Gotoh A, Kirito K, Noguchi M, Koike M, Sakamoto J, Oba K, Komatsu N.
Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1
Transcript Decline for Achievement of
Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo
Yamanashi Cooperative Study Group. Oncology. 2017. [Epub ahead of print]
Ueda K, Ikeda K, Ikezoe T, Harada-Shirado K, Ogawa K, Hashimoto Y, Sano T, Ohkawara H, Kimura S,
Shichishima-Nakamura A, Nakamura Y, Shikama Y, Mori T, Mason PJ, Bessler M, Morishita S, Komatsu N, Shide K,
Shimoda K, Koide S, Aoyama K, Oshima M, Iwama
A, Takeishi Y. Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms. Blood
Advances. 2017;1(15):1001-15.
Sunami Y, Araki M, Kan S, Ito A, Hironaka Y, Imai M, Morishita S, Ohsaka A, Komatsu N. Histone Acetyltransferase
p300/CREB-binding Protein-associated Factor (PCAF) Is Required for All-trans-retinoic Acid-induced Granulocytic
Differentiation in Leukemia
Cells. J Biol Chem. 2017;292(7):2815-29.
Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Fujioka I, Asou N,
Komatsu N, Kizaki M, Hatta Y, Kawaguchi T. Introduction of second-generation tyrosine kinase inhibitors may
reduce the prognostic impact of high-risk
patients, according to the European treatment and outcome study (EUTOS) score. Leuk Lymphoma. 2017:1-8.
Sakurai H, Harada Y, Ogata Y, Kagiyama Y, Shingai N, Doki N, Ohashi K, Kitamura T, Komatsu N, Harada H.
Overexpression of RUNX1 short isoform has an important role in the development of
myelodysplastic/myeloproliferative neoplasms. Blood Advances. 2017;1(18):1382-6.
Misawa K, Yasuda H, Araki M, Ochiai T, Morishita S, Nudejima M, Hironaka Y, Shirane S, Edahiro Y, Gotoh A,
Ohsaka A, Komatsu N. The 2016 WHO diagnostic criteria for polycythemia vera renders an accurate diagnosis to a
broader range of patients including
masked polycythemia vera: Comparison with the 2008 WHO diagnostic criteria. Am J Hematol. 2017;92(7):E128-e30.
Komatsu N, Kirito K, Shimoda K, Ishikawa T, Ohishi K, Ohyashiki K, Takahashi N, Okada H, Amagasaki T, Yonezu T,
Akashi K. Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese
patients with myelofibrosis. Int
J Hematol. 2017;105(3):309-17.
Kobayashi T, Nannya Y, Ichikawa M, Oritani K, Kanakura Y, Tomita A, Kiyoi H, Kobune M, Kato J, Kawabata H,
Shindo M, Torimoto Y, Yonemura Y, Hanaoka N, Nakakuma H, Hasegawa D, Manabe A, Fujishima N, Fujii N, Tanimoto M,
Morita Y, Matsuda A, Fujieda A,
Katayama N, Ohashi H, Nagai H, Terada Y, Hino M, Sato K, Obara N, Chiba S, Usuki K, Ohta M, Imataki O, Uemura M,
Takaku T, Komatsu N, Kitanaka A, Shimoda K, Watanabe K, Tohyama K, Takaori-Kondo A, Harigae H, Arai S, Miyazaki
Y, Ozawa K, Kurokawa M. A
nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study). Am J Hematol.
2017;92(12):1324-32.
Kitahara H, Maruyama D, Maeshima AM, Makita S, Miyamoto KI, Fukuhara S, Munakata W, Suzuki T, Kobayashi Y,
Tajima K, Terauchi T, Kurihara H, Taniguchi H, Komatsu N, Tobinai K. Prognosis of patients with peripheral T
cell lymphoma who achieve complete
response after CHOP/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment.
Ann Hematol. 2017;96(3):411-20.
Katayama Y, Azechi T, Miyazaki M, Takata T, Sekine M, Matsui H, Hanaki H, Yahara K, Sasano H, Asakura K, Takaku
T, Ochiai T, Komatsu N, Chambers HF. Prevalence of Slow-growth Vancomycin Non-susceptibility In
Methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2017;61(11):e00452-17.
Iriyama N, Tokuhira M, Takaku T, Sato E, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Fujioka I, Hatta Y,
Kizaki M, Komatsu N, Asou N, Kawaguchi T. Incidences and outcomes of therapy-related chronic myeloid leukemia in
the era of tyrosine kinase inhibitors:
Surveillance of the CML Cooperative Study Group. Leuk Res. 2017;54:55-8.
Ikuta K, Hatayama M, Addo L, Toki Y, Sasaki K, Tatsumi Y, Hattori A, Kato A, Kato K, Hayashi H, Suzuki T, Kobune
M, Tsutsui M, Gotoh A, Aota Y, Matsuura M, Hamada Y, Tokuda T, Komatsu N, Kohgo Y. Iron overload patients with
unknown etiology from national
survey in Japan. Int J Hematol. 2017;105(3):353-60.
Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M, Mathias J, Komatsu N, Boothroyd RN,
Spierer A, Perez Ronco J, Taylor-Stokes G, Waller J, Mesa RA. The impact of myeloproliferative neoplasms (MPNs)
on patient quality of life and
productivity: results from the international MPN Landmark survey. Ann Hematol.2017;96(10):1653-65.
Tanaka M, Tashiro H, Omer B, Lapteva N, Ando J, Ngo M, Mehta B, Dotti G, Kinchington PR, Leen AM, Rossig C,
Rooney CM. Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen
Receptor (CAR)-Modified T Cells.
Clin Cancer Res.2017;23(14):3499-509.
Tsukune Y, Sasaki M, Odajima T, Sunami K, Takei T, Moriuchi Y, Iino M, Isoda A, Nakaya A, Muta T, Miyake T,
Miyazaki K, Shimizu T, Nakajima K, Igarashi A, Nagafuji K, Kurihara T, Aoyama T, Sugimori H, Komatsu N.
Incidence and risk factors of hepatitis
B virus reactivation in patients with multiple myeloma in an era with novel agents: a nationwide retrospective
study in Japan. Blood Cancer J. 2017; 7(12): 631.
Saito A, Isoda A, Kojima M, Yokohama A, Tsukune Y, Sasaki M, Ito S, Ohtsu A, Koike M, Murayama K, Moriya K,
Tamura H, Matsumoto M, Nakahashi H, Tanosaki S, Sakura T, Kawamura T, Miyanaga T, Nakamura N, Murakami H, Handa
H, Tsukamoto N. Retrospective analysis
of prognostic factors for Waldenstrӧm macroglobulinemia: a multicenter cooperative study in Japan. Int J
Hematol. 2017; 106(5): 681-690.
総説
Imai M, Araki M, Komatsu N. Somatic mutations of calreticulin in myeloproliferative neoplasms. Int J Hematol.
2017;105(6):743-7.
Araki M, Komatsu N. Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in
myeloproliferative neoplasms. Cancer Sci. 2017;108(10):1907-12.
Watanabe N, Yasuda H, Morishita S, Aota Y, Tomomatsu J, Tanaka M, Ohsaka A, Komatsu N. Richter's Syndrome
with Hypercalcemia Induced by Tumor-Associated Production of Parathyroid Hormone-Related Peptide. Case Rep
Oncol. 2017;10(1):123-6.
Sekiguchi Y, Wakabayashi M, Takizawa H, Sugimoto K, Tomita S, Izumi H, Nakamura N, Sawada T, Ohta Y, Komatsu N,
Noguchi M. A case of Waldenstrom Macroglobulinemia in which intermittent one-day administration cycles of
bendamustine were effective for alleviation
of nausea and maintenance of remission. J Clin Exp Hematop. 2017;57(2):79-81.
Sekiguchi Y, Takizawa H, Inano T, Fukuda Y, Wakabayashi M, Sugimoto K, Tomita S, Izumi H, Nakamura N, Sawada T,
Ohta Y, Komatsu N, Noguchi M. Three cases of relapsed/refractory multiple myeloma under hemodialysis treated
with panobinostat/bortezomib/dexamethasone
(FVD). Int J Hematol.2017;106(4):581-7.
Ikeda K, Ueda K, Sano T, Ogawa K, Ikezoe T, Hashimoto Y, Morishita S, Komatsu N, Ohto H, Takeishi Y. The
Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia
Vera Myelofibrosis Patient with a JAK2
Exon 12 Mutation. Intern Med. 2017;56(13):1705-10.
Iizuka K, Ando J, Masuda A, Ochiai T, Tomomasa R, Yasuda H, Takaku T, Ota Y, Yao T, Gotoh A, Komatsu N. Acute
exacerbation of organizing pneumonia leading to sudden death in a patient with sarcoidosis-lymphoma syndrome.
Rinsho Ketsueki. 2017;58(8):927-32.
Ando J, Masuda A, Iizuka K, Ochiai T, Shingai N, Yasuda H, Homma Y, Kobayashi E, Morishita E, Komatsu N. Factor
XI deficiency as a result of a novel Tyr347Stop nonsense mutation in an elderly Japanese woman. Geriatr Gerontol
Int. 2017;17(6):1029-31.
Sano K, Homma Y, Baba T, Ando J, Matsumoto M, Kobayashi H, Yuasa T, Kaneko K. Total hip arthroplasty via the
direct anterior approach with Kerboull-type acetabular reinforcement device for an elderly female with factor XI
deficiency. Sicot j. 2017;3:11.
海外学会発表
Tsukune Y, Sasaki M, Odajima T, Isoda A, Sumami K, Takei T, Taniguchi H, Iino M, Nakaya A, Muta T, Miyake T,
Miyazaki K, Shimizu T, Nakajima K, Igarashi A, Nagafuji K, Kurihara T, Uchino Y, Komatsu N, Hepatitis B virus
reactivation in multiple myeloma
patients in the era of novel agents: a nationwide retrospective study in Japan. 16th International Myeloma
Workshop,Delhi, India, March 2,2017.
Takei H, Mano S, Masubuchi N, Mizukami Y, Morishita S, Imai M, Edahiro Y, Hironaka Y, Nudejima M, Tsuneda S,
Endo H, Nakamura S, Eto K, Ohsaka A, Araki M, Komatsu N, editors. Establishment of an in vitro model for the
skewed megakaryopoiesis by calreticulin
mutation in human cells. 22nd Congress of the European Hematology Association; 2017; Madrid; Spain.
Masubuchi N, Araki M, Hayashi E, Yang Y, Imai M, Kihara Y, Mizukami Y, Hironaka Y, Takei H, Edahiro Y, Ohsaka A,
N. K, editors. Localization of Mutant Calreticulin in the Golgi Apparatus Is Required for Its Oncogenic
Capacity. 59th Annual Meeting of the
American Society of Hematology and Exposition; 2017; Atlanta, USA.
Sunakawa M, Tamura H, Ishibashi M, Sasaki M, Handa H, Imai Y, Tanaka J, Tanosaki S, Ito S, Inokuchi K. Clinical
impact and possible immunosuppressive function of soluble B7-H1(PD-L1) in multiple myeloma. 16th International
Myeloma Workshop, Delhi, March
3,2017.
Kaito Y, Tamura H, Soeda S, Asayama T, Ishibashi M, Sasaki M, Handa H, Imai Y, Tanaka J, Tanosaki S, Ito S,
Inokuchi K. Serum soluble SLAMF7 with disease progression in multiple myeloma and may affect anti-SLAMF7
antibody therapy. 16th International Myeloma
Workshop, Delhi, India,March 2,2017.
高橋直人, 中世古知昭, 脇田久, 得平道英, 三谷絹子, 野口雅章, 木村文彦, 三浦昌朋: DMR and TFR following 2-year consolidation by Nilotinib in
patients with CML: STAT trial in Japan, 第79回日本血液学会学術集会;東京国際フォーラム 2017年10月20日
若林睦, 関口康宣, 坂尻さくら, 杉元啓二, 瀧澤春子, 飯塚弘子, 小松則夫, 野口雅章: Retrospective analysis of AE and manage in 23 patients treated
with bendamustine at our department. 第79回日本血液学会学術集会;東京国際フォーラム 2017年10月21日
瀧澤春子, 関口康宣, 坂尻さくら, 杉元啓二, 若林睦, 飯塚弘子, 小松則夫, 野口雅章: ET was difficult to differentiate from PMF/early that was
treated with ruxolitinib, to preleukemia. 第79回日本血液学会学術集会;東京国際フォーラム 2017年10月21日
野口雅章, 小松則夫, 小池道明, 木崎昌弘, 片山直之, 土橋史明, 薄井紀子, 桐戸敬太: Clinical Performance Study of a novel JAK2V617F mutation
quantitative kits for patients with Ph-MPN. 第79回日本血液学会学術集会;東京国際フォーラム 2017年10月21日
舛井嘉大, 関口康宣, 坂尻さくら, 杉元啓二, 若林睦, 瀧澤春子, 飯塚弘子, 小松則夫, 野口雅章: A primary bone marrow low grade B-cell lymphoma.
第79回日本血液学会学術集会;東京国際フォーラム 2017年10月21日.
Tsukune Y, Sasaki M, Sunami K, Suzuki K, Taniguchi H, Iino M, Isoda A, Nakaya A, Muta T, Miyake T, Miyazaki K,
Shimizu T, Nakajima K, Igarashi A, Nagafuji K, Kurihara T, Uchino Y, Komatsu N. HBV reactivation in MM patients
in the novel agents era: A nationwide
retrospective study in Japan., 第79回日本血液学会学術集会;東京国際フォーラム 2017年10月21日
Tokuhira M, Kimura Y, Sugimoto K, Nakazato T, Ishikawa M, Fujioka I, Takaku T, Iriyama N, Sato E, Fujita H,
Yoshihiro Hatta, Komatsu N, Asou N, Kizaki M, Kawaguchi T. Efficacy and safety of the reduced nilotinib therapy
in patients with newly diagnosed
chronic myeloid leukemia. 第79回日本血液学会学術集会;東京国際フォーラム 2017年10月21日
Shingai N, Harada Y, Sakurai H, Ogata Y, Akahane K, Nishio M, Doki N, Ohashi K, Hagihara M, Komatsu N, Harada H.
Splicing factor mutations may define the phenotypes and disease evolution of MDS. 第79回日本血液学会学術集会;東京国際フォーラム
2017年10月21日
Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T, Sugimoto K, Fujita H, Fujioka I, Hatta Y,
Kizaki M, Komatsu N, Asou N, Kawaguchi T. The introduction of 2nd generation TKIs may reduce the prognostic
impact of EUTOS high-risk patients.
第79回日本血液学会学術集会;東京国際フォーラム 2017年10月21日
Kinoshita R, Ishibashi M, Inokuchi K, Handa H, Sasaki M, Komatsu N, Imai Y, Tanaka N, Tanaka J, Tanosaki S, Ito
S, Isoda A, Matsumoto M, Koike M, Tamura H. Evalution of staging and prognostic factors in multiple
myeloma:KT-MM prognostic analysis. 第79回日本血液学会学術集会;東京国際フォーラム
2017年10月21日
Nakazato T, Iriyama N, Ishikawa M, Sato E, Takaku T, Fujioka I, Sugimoto K, Fujita H, Kizaki M, Komatsu N, Asou
N, Tokuhira M, Kawaguchi T. Incidence of Second Malignancies of Chronic Myeloid Leukemia During Treatment with
Tyrosine Kinase Inhibitors.
第79回日本血液学会学術集会;東京国際フォーラム 2017年10月21日
Masubuchi N, Araki M, Hayashi E, Yang Y, Imai M, Mizukami Y, Hironaka Y, Takei H, Morishita S, Kihara Y, Edahiro
Y, Ohsaka A, Komatsu N. Engagement of mutant calreticulin and MPL in a cellular compartment is required for MPL
activation. 第79回日本血液学会学術集会;東京国際フォーラム
2017年10月21日
Umezawa G, Ishibashi M, Tamura H, Asayama T, Kuribayashi-Hamada Y, Moriya K, Imai Y, Tanaka J, Handa H, Sasaki
M, Tanosaki S, Ito S, Komatsu N, Inokuchi K. Clinical significance of CD86 soluble from and cell-surface
expression in multiple myeloma patients.
第79回日本血液学会学術集会;東京国際フォーラム 2017年10月21日
Yoshimi A, Toya T, Nannya Y, Takaoka K, Kirito K, Ito E, Nakajima H, Hayashi Y, Takahashi T, Moriya-Saito A,
Suzuki K, Harada H, Komatsu N, Usuki K, Ichikawa M, Kurokawa M. Spectrum of clinical and genetic features of
patients with inherited platelet
disorder with suspected predisposition to hematological malignancies: a nationwide survey in Japan. Annals of
oncology : official journal of the European Society for Medical Oncology / ESMO. 2016;27(5):887-95.
Tsukune Y, Komatsu N. Management of Adult Chronic Immune Thrombocytopenia in Japan: Patient and Hematologist
Perspectives from a Multi-center Cross-sectional Questionnaire Survey. Internal medicine (Tokyo, Japan).
2016;55(17):2379-85.
Tsukune Y, Sasaki M, Odajima T, Isoda A, Matsumoto M, Koike M, Tamura H, Moriya K, Ito S, Asahi M, Imai Y,
Tanaka J, Handa H, Koiso H, Tanosaki S, Hua J, Hagihara M, Yahata Y, Suzuki S, Watanabe S, Sugimori H, Komatsu
N. Incidence and clinical background
of hepatitis B virus reactivation in multiple myeloma in novel agents' era. Annals of hematology.
2016;95(9):1465-72.
Miyasaka N, Miura O, Kawaguchi T, Arima N, Morishita E, Usuki K, Morita Y, Nishiwaki K, Ninomiya H, Gotoh A,
Imashuku S, Urabe A, Shichishima T, Nishimura J, Kanakura Y. Pregnancy outcomes of patients with paroxysmal
nocturnal hemoglobinuria treated with
eculizumab: a Japanese experience and updated review. International journal of hematology. 2016;103(6):703-12.
Mitsumori T, Komatsu N, Kirito K. A CSF3R T618I Mutation in a Patient with Chronic Neutrophilic Leukemia and
Severe Bleeding Complications. Internal medicine (Tokyo, Japan). 2016;55(4):405-7.
Matsuoka S, Ishii Y, Nakao A, Abe M, Ohtsuji N, Momose S, Jin H, Arase H, Sugimoto K, Nakauchi Y, Masutani H,
Maeda M, Yagita H, Komatsu N, Hino O. Establishment of a Therapeutic Anti-Pan HLA-Class II Monoclonal Antibody
That Directly Induces Lymphoma
Cell Death via Large Pore Formation. PloS one. 2016;11(3):e0150496.
Kobayashi Y, Saita Y, Nishio H, Ikeda H, Takazawa Y, Nagao M, Takaku T, Komatsu N, Kaneko K. Leukocyte
concentration and composition in platelet-rich plasma (PRP) influences the growth factor and protease
concentrations. Journal of orthopaedic science
: official journal of the Japanese Orthopaedic Association. 2016;21(5):683-9.
Iizuka K, Yokomizo T, Watanabe N, Tanaka Y, Osato M, Takaku T, Komatsu N. Lack of Phenotypical and Morphological
Evidences of Endothelial to Hematopoietic Transition in the Murine Embryonic Head during Hematopoietic Stem Cell
Emergence. PloS one. 2016;11(5):e0156427.
Ichikawa K, Edahiro Y, Gotoh A, Iiduka K, Komatsu N, Koike M. Co-occurrence of hyperleukocytosis and elevated
fibrin-fibrinogen degradation product levels is a risk factor for early intracranial hemorrhage in patients with
de novo acute leukemia. International
journal of hematology. 2016;104(5):612-20.
Baba T, Tanabe Y, Yoshikawa S, Yamanishi Y, Morishita S, Komatsu N, Karasuyama H, Hirao A, Mukaida N.
MIP-1alpha/CCL3-expressing basophil-lineage cells drive the leukemic hematopoiesis of chronic myeloid leukemia
in mice. Blood. 2016;127(21):2607-17.
Araki M, Yang Y, Masubuchi N, Hironaka Y, Takei H, Morishita S, Mizukami Y, Kan S, Shirane S, Edahiro Y, Sunami
Y, Ohsaka A, Komatsu N. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant
myeloproliferative neoplasms. Blood.
2016;127(10):1307-16.
Yasuda H, Tsutsui M, Ota Y, Misawa K, Gotoh A, Hamano Y, Komatsu N. Blastic plasmacytoid dendritic cell neoplasm
accompanied by autoimmune hemolytic anemia achieving complete remission with hydroxyurea and steroids.
Geriatrics & gerontology international.
2016;16(3):396-8.
Tsukune Y, Sasaki M, Odajima T, Isoda A, Matsumoto M, Koike M, Tamura H, Moriya K, Ito S, Asahi M, Imai Y,
Tanaka J, Handa H, Koiso H, Tanosaki S, Hua J, Hagihara M, Yahata Y, Suzuki S, Watanabe S, Sugimori H, Komatsu
N. Incidence and clinical background
of hepatitis B virus reactivation in multiple myeloma in novel agents' era. Annals of hematology.
2016;95(9):1465-72.
Sunami Y, Ichikawa K, Edahiro Y, Komatsu N, Koike M. Safe and effective induction therapy with CHASER for
primary testicular lymphoma with central nervous system involvement. Int J Clin Exp Med. 2016;9(9):18645-9.
Sekiguchi Y, Shirane S, Takizawa H, Wakabayashi M, Sugimoto KJ, Tomita S, Izumi H, Nakamura N, Sawada T, Ohta Y,
Komatsu N, Noguchi M. T-cell lymphoma complicated by myelofibrosis: report of three cases and review of
literature. Int J Clin Exp Pathol.
2016;9(8):7836-53.
Sekiguchi Y, Ichikawa K, Takizawa H, Wakabayashi M, Sugimoto K, Tomita S, Izumi H, Nakamura N, Sawada T, Hirai
T, Sekikawa I, Ohta Y, Komatsu N, Noguchi M. Epstein-Barr virus-negative and CD56-positive primary central
nervous system lymphoproliferative
disorder (diffuse large B-cell lymphoma): a case of report and review of the literature. Int J Clin Exp Pathol.
2016;9(8):8017-26.
Sekiguchi Y, Inano T, Fukuda Y, Takizawa H, Wakabayashi M, Sugimoto KJ, Tomita S, Izumi H, Nakamura N, Sawada T,
Ohta Y, Komatsu N, Noguchi M. A long-term favorable response and effective control of neutropenia obtained by
low-dose pomalidomide treatment
in a patient with relapsed refractory multiple myeloma: a case report. Int J Clin Exp Med. 2016;9(11):22561-9.
Nakamura R, Ueno Y, Ando J, Matsuda H, Masuda A, Iiduka K, Shingai N, Takanashi M, Yokoyama K, Komatsu N,
Hattori N. Clinical and radiological CLIPPERS features after complete remission of peripheral T-cell lymphoma,
not otherwise specified. Journal of
the neurological sciences. 2016;364:6-8.
Mitsumori T, Komatsu N, Kirito K. A CSF3R T618I Mutation in a Patient with Chronic Neutrophilic Leukemia and
Severe Bleeding Complications. Internal medicine (Tokyo, Japan). 2016;55(4):405-7.
Mohammad S, Gotoh A, Morishita S, Komatsu N. Imatinib-sensitive myeloid neoplasm with low allele burden of
FIP1L1-PDGFRA fusion gene in an elderly patient. Geriatrics & gerontology international. 2016;16(12):1346-8.
Edahiro Y, Ichikawa K, Suzuki H, Yasuda H, Koike M, Komatsu N. Successful perioperative management of factor XI
deficiency with administration of fresh-frozen plasma in a subdural hematoma patient. Geriatrics &
gerontology international. 2016;16(1):143-4.
和文症例報告
Sunami Y, Gotoh A, Watanabe N, Edahiro Y, Hamano Y, Harada H, Komatsu N. [Chronic Myelomonocytic Leukemia with
Myelofibrosis Resulting in Sudden Massive Pleural Effusion during Cytoreductive Therapy with Hydroxycarbamide].
Gan to kagaku ryoho Cancer &
chemotherapy. 2016;43(10):1223-6.
Ando J, Masuda A, Iizuka K, Ochiai T, Takaku T, Osawa T, Shimada E, Watanabe Y, Komatsu N, Osaka A. Congenital
haptoglobin deficiency discovered on the occasion of anaphylaxis induced by platelet concentrate transfusion.
[Rinsho ketsueki] The Japanese
journal of clinical hematology. 2016;57(12):2507-11.
Araki M, Yang Y, Masubuchi N, Hironaka Y, Takei H, Morishita S, Mizukami Y, Kan S, Shirane S, Edahiro Y, Sunami
Y, Ohsaka A, Komatsu N. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant
myeloproliferative neoplasms ,21st
EHA Congress, Copenhagen, Denmark, June 9-12, 2016.
Iriyama N, Takaku T, Sato E, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Tokuhira M, Kawaguchi T. Clinical
Entity and Outcomes of Therapy-Related Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors:
Surveillance By the Chronic Myeloid
Leukemia Cooperative Study Group, 58th ASH Annual Meeting and Exposition, San Diego, USA, December 3-6, 2016.
Nishiwaki K, Sugimoto KJ, Tamaki S, Hisatake J, Yokoyama H, Igarashi T, Shinagawa A, Sugawara T, Hara S,
Fujikawa K, Shimizu S, Toshiaki Y, Tojo A, Wakita H. Optimal Treatment Strategy with Nilotinib for Patients with
Newly Diagnosed Chronic Myelogenous
Leukemia in the Chronic Phase Based on Early Achievement of Deep Molecular Response (MR4.5) : First Report from
N-Road, a Phase II Study in Japan., 58th ASH Annual Meeting and Exposition, San Diego, USA, December 3-6, 2016.
Isobe Y, Masuda A, Sugimoto K, Komatsu N. The Long Form of Cellular FLIP Renders NK-Cell Lymphoma Cells
Resistant to Fas-Mediated Apoptosis, 58th ASH Annual Meeting and Exposition, San Diego, USA, December 3-6, 2016.
池之内穣, 関口康宣, 杉元啓二, 若林睦, 瀧澤春子, 小松則夫, 野口雅章: BMではなくリンパ節と漿膜におけるIgAκ+ CD20+ CD19-形質細胞腫の典型的な1症例(A typical case of
IgA kappa+ CD20+ CD19-plasmacytoma not in BM but in lymph node and serosa, 第56回日本リンパ網内系学会総会; ホテル日航熊本 2016年9月3日.
Okuda Y, Aota Y, Yokoyama T, Kitagawa N, Shinozawa K, Amano K, Fukutake K, Gotoh A, Komatsu N. Anticagulant
therapy for a vein thrombosis Caucasian patient with the Factor V Leiden mutation. , 第78回日本血液学会学術集会; パシフィコ横浜
2016年10月13-15日
Ochiai T, Araki M, Misawa K, Morishita S, Nudejima M, Hironaka Y, Shirane S, Edahiro Y, Sunami Y Gotoh A, Ohsaka
A, Komatsu N. Clinical characteristics of BCSH criteria defined PV and ET patients in Japan. , 第78回日本血液学会学術集会;
パシフィコ横浜 2016年10月13-15日
Tsutsui M, Gotoh A, Araki M, Morishita S, Komatsu N. Impact of mutations on efficacy of anagrelide in Japanese
patients with essential thrombocythemia. , 第78回日本血液学会学術集会; パシフィコ横浜 2016年10月13-15日
Misawa K, Araki M, Ochiai T, Morishita S, Nudejima M, Hironaka Y, Shirane S, Edahiro Y, Sunami Y, Gotoha A,
Ohsaka A, Komatsu N. Differential clinical features by sbtypes of Calreticulin mutation in myeloproliferative
neoplasms. , 第78回日本血液学会学術集会; パシフィコ横浜
2016年10月13-15日
Fujioka I, Takaku T, Watanabe N, Gotoh A, Komatsu N. Assessment of treatment response by international scale in
Japanese patients with chronic phase CML. , 第78回日本血液学会学術集会; パシフィコ横浜 2016年10月13-15日
Iizuka K, Andou J, Ochiai T, Shirane S, Masuda A, Gotoh A, Koike M, Komatsu N. Efficacy of GDP for
anti-L-asparaginase antibody positive and /or SMILE resistant NK/T lymphpma. , 第78回日本血液学会学術集会; パシフィコ横浜
2016年10月13-15日
Soeda S, Tamura H, Ishibashi M, Sasaki M, Handa H, Imai Y, Tanosaki S, Isoda A, Matsumoto M, Ito S, Koike M,
Komatsu N, Inokuchi K. The impact of serum soluble SLAMF7 on myeloma pathogenesis and anti-SLAMF7 antibody-based
therapy. , 第78回日本血液学会学術集会; パシフィコ横浜
2016年10月13-15日
Tsubota A, Tamura H, Ishibashi M, Sasaki M, Handa H, Imai Y, Tanosaki S, Isoda A, Matsumoto M, Ito S, Koike M,
Komastu N, Inokuchi K. Clinical significance of serum soluble and plasma cell-surface SLAMF3 levels in multiple
myeloma. , 第78回日本血液学会学術集会; パシフィコ横浜
2016年10月13-15日
Moriya K, Ishibashi M, Tamura H, Handa H, Sasaki M, Isoda A, Imai Y, Ito S, Tanosaki S, Inokuchi K, Komastu N,
Matsumoto M, Tanaka J, Koike M. Clinical significance of IL-6 and IGF-1 receptor expression on myeloma cells. ,
第78回日本血液学会学術集会; パシフィコ横浜 2016年10月13-15日
Yamada A, Tamura H, Ishibashi M, Sasaki M, Komastu N, Handa H, Imai Y, Tanosaki S, Ito S, Isoda A, Matsumoto M,
Koike M, Inokuchi K. An aggressive myeloma patient with high KL-6 production and clinical impact of serum KL-6
in myeloma. , 第78回日本血液学会学術集会;
パシフィコ横浜 2016年10月13-15日
Sugimoto K, Suzuki H, Fujimura T, Ono A, Kaga N, Isobe Y, Sasaki M, Taka H, Miyazono K, Komatsu N. Association
of glutaminase high expression with L-asparaginase-sensitivity in lymphoid leukemia cells. , 第78回日本血液学会学術集会;
パシフィコ横浜 2016年10月13-15日
瀧澤春子, 関口康宜, 若林睦, 杉元啓二, 小松則夫, 野口雅章: A Case of AE Free Remission of RRMM in Response to FVD during Maintenance
Hemodialysis. , 第78回日本血液学会学術集会; パシフィコ横浜 2016年10月13-15日
小池道明, 飯塚和秀, 重光文子, 白根脩一, 小松則夫: Efficacy of cyclosporin A therapy for three cases of angioimmunoblastic T cell
lymphoma (AITL), 第78回日本血液学会学術集会; パシフィコ横浜 2016年10月13-15日
佐藤恵理子, 野口雅章, 小池道明, 森下総司, 大津洋, 小松則夫: Stop trial against CMP-CP in CMR patients who had received sequential TKIs;
an interim analysis. , 第78回日本血液学会学術集会; パシフィコ横浜 2016年10月13-15日
Masubuchi N, Araki M, Yang Y, Hironaka Y, Takei H, Morishita S, Mizukami Y, Kan S, Ohsaka A, Komatsu N. Cell
surface localization of mutant calreticulin that induces myeloproliferative neoplasms (MPNs). , 第78回日本血液学会学術集会;
パシフィコ横浜 2016年10月13-15日
Yasuda H, Tsutsui M, Tanaka M, Araki M, Morishita S, Sasaki M, Ohsaka A, Komatsu N. Accurate flow cytometric
gating of the large lymphocyte region is a powerful screening method for detecting hairy cell leukemia
presenting with a low tumor burden. Internal
medicine (Tokyo, Japan). 2015;54(10):1287-9. Epub 2015/05/20.
Yasuda H, Fujiwara N, Ishizaki Y, Komatsu N. Anemia attributed to vitamin B6 deficiency in
post-pancreaticoduodenectomy patients. Pancreatology : official journal of the International Association of
Pancreatology (IAP) [et al]. 2015;15(1):81-3. Epub 2014/12/30.
Sugimoto K, Suzuki HI, Fujimura T, Ono A, Kaga N, Isobe Y, Sasaki M, Taka H, Miyazono K, Komatsu N. A clinically
attainable dose of L-asparaginase targets glutamine addiction in lymphoid cell lines. Cancer science. 2015. Epub
2015/09/04.
Shirane S, Araki M, Morishita S, Edahiro Y, Takei H, Yoo Y, Choi M, Sunami Y, Hironaka Y, Noguchi M, Koike M,
Noda N, Ohsaka A, Komatsu N. JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative
neoplasms. Haematologica. 2015;100(2):e46-8.
Epub 2014/11/16.
Shirane S, Araki M, Morishita S, Edahiro Y, Sunami Y, Hironaka Y, Noguchi M, Koike M, Sato E, Ohsaka A, Komatsu
N. Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from
polycythemia vera and essential
thrombocythemia. International journal of hematology. 2015;101(2):148-53. Epub 2014/12/20.
Ohsaka A, Hirota-Komatsu S, Araki M, Komatsu N. Platelet-derived growth factor receptors form complexes with
neuropilin-1 during megakaryocytic differentiation of thrombopoietin-dependent UT-7/TPO cells. Biochemical and
biophysical research communications.
2015;459(3):443-9. Epub 2015/03/10.
Morishita S, Takahashi K, Araki M, Hironaka Y, Sunami Y, Edahiro Y, Tsutsui M, Ohsaka A, Tsuneda S, Komatsu N.
Melting curve analysis after T allele enrichment (MelcaTle) as a highly sensitive and reliable method for
detecting the JAK2V617F mutation.
PloS one. 2015;10(3):e0122003. Epub 2015/03/21.
Liew EL, Araki M, Hironaka Y, Mori S, Tan TZ, Morishita S, Edahiro Y, Ohsaka A, Komatsu N. Identification of
AIM2 as a downstream target of JAK2V617F. Experimental hematology & oncology. 2015;5:2. Epub 2016/01/30.
Kummalue T, Inoue T, Miura Y, Narusawa M, Inoue H, Komatsu N, Wanachiwanawin W, Sugiyama D, Tani K. Ribosomal
protein L11 and retinol dehydrogenase 11 induced erythroid proliferation without erythropoietin in UT-7/Epo
erythroleukemic cells. Experimental
hematology. 2015. Epub 2015/04/02.
Hirokawa M, Sawada K, Fujishima N, Teramura M, Bessho M, Dan K, Tsurumi H, Nakao S, Urabe A, Fujisawa S,
Yonemura Y, Kawano F, Oshimi K, Sugimoto K, Matsuda A, Karasawa M, Arai A, Komatsu N, Harigae H, Omine M, Ozawa
K, Kurokawa M. Long-term outcome of
patients with acquired chronic pure red cell aplasia (PRCA) following immunosuppressive therapy: a final report
of the nationwide cohort study in 2004/2006 by the Japan PRCA collaborative study group. British journal of
haematology. 2015. Epub 2015/03/27.
Harada-Shirado K, Ikeda K, Ogawa K, Ohkawara H, Kimura H, Kai T, Noji H, Morishita S, Komatsu N, Takeishi Y.
Dysregulation of the MIRLET7/HMGA2 axis with methylation of the CDKN2A promoter in myeloproliferative neoplasms.
British journal of haematology.
2015;168(3):338-49. Epub 2014/09/23.
2014年
英文原著
Shirane S, Araki M, Morishita S, Edahiro Y, Takei H, Choi M, Sunami Y, Hironaka Y, Noguchi M, Koike M, Noda N,
Ohsaka A, Komatu N.:JAK2, CARL, and MPL mutation specterum in Japanese myeloproliferative neoplasms
patients.:Haematologica, 2014; 99(5): 625-634
Aoki T, Izutsu K, Suzuki R, Nakaseko C, Arima H, Shimada K, Tomita A, Sasaki M, Takizawa J, Mitani K, Igarashi
T, Maeda Y, Fukuhara N, Ishida F, Niitsu N, Ohmachi K, Takasaki H, Nakamura N, Kinoshita T, Nakamura S, Ogura
M.:Prognostic significance of
pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell
lymphoma: a multicenter retrospective study in Japan.:Haematologica, 2014; 99: 1817-1825
Yasuda H, Takaku T, Tomomatsu J, Hosone M, Tanaka H, Komatsu N.:Spontaneous Regression of Cutaneous Blastic
Plasmacytoid Dendritic Cell Neoplasm Followed by Acute Monocytic Leukemia Evolving from Myelodysplastic
Syndrome.:Intern Med, 2014; 53(23): 2717-2720.
Edahiro Y, Morishita S, Takahashi K, Hironaka Y, Yahata Y, Sunami Y, Shirane S, Tsutsui M, Noguchi M, Koike M,
Imai K, Kirito K, Noda N, Sekiguchi Y, Tsuneda S, Ohsaka A, Araki M, Komatsu N.:JAK2V617F mutation status and
allele burden in classical Ph-negative
myeloproliferative neoplasms in Japan.:Int J Hematol, 2014; 99: 625-634.
Komatsu N.:Guest editorial: Acute promyelocytic leukemia: change from "highly fatal to highly curable"
leukemia.:Int J Hematol, 2014; 100: 16-17
Takei H, Morishita S, Araki M, Edahiro Y, Sunami Y, Hironaka Y, Noda N, Sekiguchi Y, Tsuneda S, Ohsaka A,
Komatsu N. :Detection of MPLW515L/K mutations and determination of allele frequencies with a single-tube PCR
assay. :PLOS ONE., 2014; 9(8): e104958
Koike M, Masuda A, Ichikawa K, Shigemitsu A, Komatsu N.:Plasmablastic lymphoma of the duodenal and jejunum.:Int
J Clin Exp pathol, 2014; 15: 4479-4483
Lam K, Muselman A, Du R, Harada Y, Scholl AG, Yan M, Matsuura S, Weng S, Harada H, Zhang DE.:Hmga2 is a direct
target gene of RUNX1 and regulates expansion of myeloid progenitors in mice.:Blood, 2014; 124(14): 2203-2212
Nakahara F, Kitaura J, Uchida T, Nishida C, Togami K, Inoue D, Matsukawa T, Kagiyama Y, Enomoto Y, Kawabata KC,
Chen-Yi L, Komeno Y, Izawa K, Oki T, Nagae G, Harada Y, Harada H, Otsu M, Aburatani H, Heissig B, Hattori K,
Kitamura T.:Hes1 promotes blast
crisis in chronic myelogenous leukemia through MMP-9 upregulation in leukemic cells.:Blood, 2014; 123(25):
3932-3942
Kimura Y, Gotoh A, Katagiri S, Hoshi Y, Uchida S, Yamasaki A, Takahashi Y, Fukutake K, Kiguchi T, Ohyashiki
K.:Transfusion-transmitted hepatitis E in a patient with myelodysplastic syndromes.:Blood Transfus, 2014; 12(1):
103-106
Uchida T, Kitaura J, Nakahara F, Togami K, Inoue D, Maehara A, Nishimura K, Kawabata KC, Doki N, Kakihana K,
Yoshioka K, Izawa K, Oki T, Sada A, Harada Y, Ohashi K, Katayama Y, Matsui T, Harada H, Kitamura T.:Hes1
upregulation contributes to the development
of FIP1L1-PDGRA-positive leukemia in blast crisis.:Exp Hematol, 2014; 42(5):369-379
Mitsumori T, Nozaki Y, Kawashima I, Yamamoto T, Shobu Y, Nakajima K, Morishita S, Komatsu N, Kirito K.:Hypoxia
inhibits JAK2V617F activation via suppression of SHP-2 function in myeloproliferative neoplasm cells. :Exp
Hematol, 2014; 42(9): 783-792
Ngo MC, Ando J, Leen AM, Ennamuri S, Lapteva N, Vera JF, Min-Venditti A, Mims MP, Heslop HE, Bollard CM,
Gottschalk S, Rooney CM.:Complementation of antigen-presenting cells to generate T lymphocytes with broad target
specificity.:J Immunother, 2014;
37(4): 193-203
Sakurai M, Kunimoto H, Watanabe N, Fukuchi Y, Yuasa S, Yamazaki S, Nishimura T, Sadahira K, Fukuda K, Okano H,
Nakauchi H, Morita Y, Matsumura I, Kudo K, Ito E, Ebihara Y, Tsuji K, Harada Y, Harada H, Okamoto S, Nakajima
H.:Impaired hematopoietic differentiation
of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients.:Leukemia, 2014; 28(12): 2344-2354
Sashida G, Harada H, Matsui H, Oshima M, Yui M, Harada Y, Tanaka S, Mochizuki-Kashio M, Wang C, Saraya A, Muto
T, Hayashi Y, Suzuki K, Nakajima H, Inaba T, Koseki H, Huang G, Kitamura T, Iwama A.:Ezh2 loss promotes
development of myelodysplastic syndrome
but attenuates its predisposition to leukaemic transformation.:Nat Commun, 2014; 5: 4177
Yoshimi A, Toya T, Kawazu M, Ueno T, Tsukamoto A, Iizuka H, Nakagawa M, Nannya Y, Arai S, Harada H, Usuki K,
Hayashi Y, Ito E, Kirito K, Nakajima H, Ichikawa M, Mano H, Kurokawa M.:Recurrent CDC25C mutations drive
malignant transformation in FPD/AML.:Nat
Commun, 2014; 5: 4770
Sekiguchi Y, Shimada A, Imai H, Wakabayashi M, Sugimoto K, Nakamura N, Sawada T, Ohta Y, Komatsu N, Noguchi M.:A
Case of Advanced Primary Thyroid Double-Hit B Cell Lymphoma in Which Complete Remission has been Maintained
After High-Dose Chemotherapy and
Autologous Peripheral Blood Stem Cell Transplantation Performed During the Second Remission, with a Review of
the Literature.:Indian J Hematol Blood Transfus, 2014; Suppl 1: 166-173.
Sekiguchi Y, Shimada A, Imai H, Wakabayashi M, Sugimoto K, Nakamura N, Sawada T, Komatsu N, Noguchi M.:Patient
with refractory multiple myeloma developing eosinophilia after lenalidomide treatment and lung cancer 9 months
later: case report and review
of the literature.:Indian J Hematol Blood Transfus, 2014; Suppl 1: 264-270
Sekiguchi Y, Yoshikawa H, Shimada A, Imai H, Wakabayashi M, Sugimoto K, Nakamura N, Sawada T, Ichinose T, Ozaki
D, Komatsu N, Noguchi M.:Acquired factor v inhibitor developing after treatment with dabigatran etexilate
methanesulfonate: a case report and
review of the literature.:Indian J Hematol Blood Transfus, 2014; Suppl 1: 275-279
Sekiguchi Y, Shimada A, Imai H, Wakabayashi M, Sugimoto K, Nakamura N, Sawada T, Komatsu N, Noguchi
M.:Spontaneous regression of a clinically-advanced histologically low-grade follicular lymphoma involving the
breast: case report and review of the literature.:Indian
J Hematol Blood Transfus, 2014; Suppl 1: 320-324
Ichikawa K, Noguchi M, Koike M, Aritaka N, Sekiguchi Y, Sunami Y, Tsutsui M, Hosone M, Hirano T, Gotoh A,
Komatsu N.:Rituximab plus a CHOP-like regimen, central nervous system prophylaxis, and contralateral testicular
irradiation for localized primary
testicular diffuse large B-cell lymphoma lead to prolonged progression-free survival.:Int J Hematol, 2014;
100(4): 370-378
Sugimoto KJ, Shimada A, Wakabayashi M, Sekiguchi Y, Izumi H, Ota Y, Komatsu N, Noguchi M.:T-cell lymphoblastic
leukemia/lymphoma with t(7;14)(p15;q32) [TCRγ-TCL1A translocation]: a case report and a review of the
literature.:Int J Clin Exp Pathol, 2014;
7(5): 2615-2623
Sekiguchi Y, Shimada A, Imai H, Wakabayashi M, Sugimoto K, Nakamura N, Sawada T, Komatsu N, Noguchi M.:A case of
recurrent autoimmune hemolytic anemia during remission associated with acute pure red cell aplasia and
hemophagocytic syndrome due to human
parvovirus B19 infection successfully treated by steroid pulse therapy with a review of the literature.:Int J
Clin Exp Pathol, 2014; 7(5): 2624-2635
Sekiguchi Y, Shimada A, Imai H, Wakabayashi M, Sugimoto K, Nakamura N, Sawada T, Komatsu N, Noguchi
M.:Intravascular large B-cell lymphoma with pontine involvement successfully treated with R-CHOP therapy and
intrathecal administration: a case report
and review of literature.:Int J Clin Exp Pathol, 2014; 7(6): 3363-3369
Sugimoto KJ, Shimada A, Ichikawa K, Wakabayashi M, Sekiguchi Y, Izumi H, Ota Y, Komatsu N, Noguchi M.:Primary
platelet-derived growth factor-producing, spindle-shaped diffuse large B-cell lymphoma of the skull: a case
report and literature review.:Int
J Clin Exp Pathol, 2014; 7(7): 4381-4390
Sekiguchi Y, Shimada A, Ichikawa K, Wakabayashi M, Sugimoto K, Kinoshita A, Suga Y, Tomita S, Izumi H, Nakamura
N, Sawada T, Ohta Y, Komatsu N, Noguchi M.:A case of post-mogamulizumab relapse of acute-type adult T-cell
leukemia/lymphoma successfully treated
with mogamulizumab and etoposide.:Int J Clin Exp Pathol, 2014; 7(9): 6278-6290
Sekiguchi Y, Shimada A, Wakabayashi M, Sugimoto K, Tomita S, Izumi H, Nakamura N, Sawada T, Ohta Y, Komatsu N,
Noguchi M.:A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete
remission was achieved and maintained
for a long period of time after VAD therapy and tandem autologous transplantation.:Int J Clin Exp Pathol, 2014;
7(9): 6313-6322
Wakabayashi M, Sekiguchi Y, Shimada A, Ichikawa K, Sugimoto K, Tomita S, Izumi H, Nakamura N, Sawada T, Ohta Y,
Komatsu N, Noguchi M:Diffuse large B-cell lymphoma solely involving bilateral adrenal glands and stomach: report
of an extremely rare case
with review of the literature.:Int J Clin Exp Pathol, 2014; 7(11): 8190-8197
Sugimoto KJ, Asahina M, Shimada A, Ichikawa K, Wakabayashi M, Sekiguchi Y, Izumi H, Ota Y, Komatsu N, Noguchi
M.:IgG3 subclass-positive primary thymic MALT lymphoma without trisomy 3 and trisomy 18: report of a case and
review of literature.:Int J Clin
Exp Pathol, 2014; 7(12): 8980-8987
Ichikawa K, Noguchi M, Koike M, Aritaka N, Sekiguchi Y, Sunami Y, Tsutsui M, Hosone M, Hirano T, Gotoh A,
Komatsu N.:Rituximab plus a CHOP-like regimen, central nervous system prophylaxis, and contralateral testicular
irradiation for localized primary
testicular diffuse large B-cell lymphoma lead to prolonged progression-free survival.:Int J Hematol, 2014;
100(4): 370-378
Sakurai H, Sugimoto KJ, Shimada A, Imai H, Wakabayashi M, Sekiguchi Y, Ota Y, Izutsu K, Takeuchi K, Komatsu N,
Noguchi M.:Primary CNS CCND1/MYC-Positive Double-Hit B-Cell Lymphoma: A Case Report and Review of the
Literature.:J Clin Oncol, 2014; Mar 31.
Mor A, Ueno Y, Shimura H; Sekiguchi Y, Noguchi M, Hamada Y, Kusunoki S, Kuroki T, Kambe T, Nishioka K, Hoshino
Y, Hattori N, Urabe T.:Motor-dominant polyneuropathy due to IgM monoclonal antibody against disialosyl
gangliosides in a patient with mantle
cell lymphoma.:J Neurol Sci, 2014; 337(1-2): 215-218
Sugimoto KJ, Shimada A, Wakabayashi M, Sekiguchi Y, Nakamura N, Sawada T, Ota Y, Komatsu N, Noguchi
M:CD56-positive adult T-cell leukemia/lymphoma: a case report and a review of the literature.:Med Mol Morphol,
2014;
Ichikawa K, Aritaka N, Ogura K, Komatsu N, Hirano T.:Strongly suspicious hemolysis caused by azacitidine in a
myelodysplastic syndrome patient. :Geriatr Gerontol Int, 2014; 14: 1006-1007
Sugimoto KJ, Shimada A, Ichikawa K, Wakabayashi M, Sekiguchi Y, Izumi H, Ota Y, Komatsu N, Noguchi M.:Primary
platelet-derived growth factor-producing, spindle-shaped diffuse large B-cell lymphoma of the skull: a case
report and literature review.:Int
J Clin Exp Pathol, 2014; 7: 4381-4390
Koike M, Masuda A, Ichikawa K, Shigemitu A, Komatus N.:Plasmablastic lasmablastic lymphoma of the duodenal and
jejunum. :Int J Clin Exp Pathol, 2014; 7: 4479-4483
Wakabayashi M, Sekiguchi Y, Shimada A, Ichikawa K, Sugimoto K, Tomita S, Izumi H, Nakamura N, Sawada T, Ohta Y,
Komatsu N, Noguchi M.:Diffuse large B-cell lymphoma solely involving bilateral adrenal glands and stomach:
report of an extremely rare case
with review of the literature.:Int J Clin Exp Pathol, 2014; 7: 8190-8197
Sugimoto KJ, Asahina M, Shimada A, Ichikawa K, Wakabayashi M, Sekiguchi Y, Izumi H, Ota Y, Komatsu N, Noguchi
M.:IgG3 subclass-positive primary thymic MALT lymphoma without trisomy 3 and trisomy 18: report of a case and
review of literature. :Int J Clin
Exp Pathol, 2014; 7: 8980-8987.
Sakurai H, Sugimoto S, Asami Shimada Hidenori Imai, Mutsumi Wakabayashi, Yasunori Ota and Koji Izutsu Kengo
Takeuchi Norio Komatsu Masaaki Noguchi.:Primary CNS CCND1/MYC-Positive Double-Hit B-Cell Lymphoma: A Case Report
and Review of the Literature.:J
Clin Oncol, 2014; Mar 31.
Sunami Y, Araki M, Hironaka Y, Morishita S, Kobayashi M, Liew E.L, Edahiro Y, Tsutsui M, Ohsaka M, Komatsu N.
Inhibition of the NAD dependent protein deacetylase SIRT2 induces granulocytic differentiation in human leukemia
cells. Plos One, 2013; 8(2):
e57633
Harada Y, Inoue D, Ding Y, Imagawa J, Doki N, Matsui H, Yahata T, Matsushita H, Ando K, Sashida G, Iwama A,
Kitamura T, Harada H. RUNX1/AML1 mutant collaborates with BMI1 overexpression in the development of human and
murine myelodysplastic syndromes.
Blood, 2013; 121(17): 3434-46
Yakura Y, Ishihara C, Kurosaki H, Kazuki Y, Komatsu N, Okada Y, Doi T, Takeya H, Oshimura M. An induced
pluripotent stem cell-mediated and integration-free factor VIII expression system. Biochem Biophys Res Commun.
2013; 431(2): 336-341
Saito F, Hatano T, Hori M, Kawamura M, Sasaki M, Aoki S, Hattori N. Lateral and dorsal column hyperintensity on
magnetic resonance imaging in a patient with myelopathy associated with intrathecal chemotherapy. Case Rep
Neurol, 2013; 5: 110-115
Tokuhira M, Takezako N, Nakazato T, Sasaki M, Handa T, Ikuta K, Ikezoe T, Matsumoto M, Aotsuka N, Taguchi J,
Shimomura S, Chin K, Ichikawa K, Usuki K, Ohyashiki K, Nara M, Kishi K, Kuroda Y, Nakamura Y, Yokoyama A, Kamata
H, Ichikawa Y, Hattori Y, Akazawa
K, Murakami H, Uchimaru K, Tomoyasu S, Suzuki K, Kizaki M. Interrim analysis of clinical trial of MBP followed
by bortezomib maintenance therapy for elderly patients with ND-MM. Clin Lymphoma Myeloma Leuk, 2013; 13(S1):
s146
Nozaki Y, Mitsumori T, Yamamoto T, Kawashima I, Shobu Y, Hamanaka S, Nakajima K, Komatsu N, Kirito K. Rituximab
activates Syk and AKT in CD20-positive B cell lymphoma cells dependent on cell membrane cholesterol levels. Exp
Hematol, 2013; 41(8): 687-696
Imagawa J, Harada Y, Shimomura T, Tanaka H, Okikawa Y, Harada H. High early death rate in elderly patients with
acute promyelocytic leukemia treated with all-trans retinoic acid combined chemotherapy. Int J Hematol, 2013;
98(2): 264-266
Morikawa D, Nojiri H, Saita Y, Kobayashi K, Watanabe K, Ozawa Y, Koike M, Asou Y, Takaku T, Kaneko K, Shimizu T.
Cytoplasmic reactive oxygen species and SOD1 regulate bone mass during mechanical unloading. J Bone Miner Res,
2013; 28(11): 2368-2380
Inoue D, Kitaura J, Togami K, Nishimura K, Enomoto Y, Uchida T, Kagiyama Y, Kawabata KC, Nakahara F, Izawa K,
Oki T, Maehara A, Isobe M, Tsuchiya A, Harada Y, Harada H, Ochiya T, Aburatani H, Kimura H, Thol F, Heuser M,
Levine RL, Abdel-Wahab O, Kitamura
T. Myelodysplastic syndromes are induced by histone methylation-altering ASXL1 mutations. J Clin Invest, 2013;
123(11): 4627-4640
Isobe Y, Hamano Y, Ito Y, Kimura H, Tsukada N, Sugimoto K, Komatsu N. A monoclonal expansion of Epstein-Barr
virus-infected natural killer cells after allogeneic peripheral blood stem cell transplantation. J Clin Virol,
2013; 56(2): 150-152
Baba T, Naka K, Morishita S, Komatsu N, Hirao A, Mukaida N. MIP-1 α/CCL3-mediated maintenance of
leukemia-initiating cells in the initiation process of chronic myeloid leukemia. J Exp Med, 2013; 210(12):
2661-2673
Suzuki HI, Matsuyama H, Noguchi M, Yao T, Komatsu N, Mano H, Sugimoto K, Miyazono K. Computational dissection of
distinct microRNA activity signatures associated with peripheral T cell lymphoma subtypes. Leukemia, 2013;
27(10): 2107-2111
Shimada A, Sugimoto KJ, Wakabayashi M, Imai H, Sekiguchi Y, Nakamura N, Sawada T, Ota Y, Komatsu N, Noguchi M.
Primary sacral non-germinal center type diffuse large B-cell lymphoma with MYC translocation: a case report and
a review of the literature.
Int J Clin Exp Pathol, 2013; 6(9): 1919-1928
Sugimoto KJ, Shimada A, Yamaguchi N, Imai H, Wakabayashi M, Sekiguchi Y, Izumi H, Ota Y, Komatsu N, Noguchi M.
Sustained complete remission of a limited-stage blastic plasmacytoid dendritic cell neoplasm followed by a
simultaneous combination of low-dose
DeVIC therapy and radiation therapy: a case report and review of the literature. Int J Clin Exp Pathol, 2013;
6(11): 2603-2608
Sugimoto KJ, Imai H, Shimada A, Wakabayashi M, Sekiguchi Y, Nakamura N, Sawada T, Izumi H, Ota Y, Komatsu N,
Noguchi M. Diffuse large B-cell lymphoma of the uterus suspected of having transformed from a marginal zone
B-cell lymphoma harboring trisomy
18: a case report and review of the literature. Int J Clin Exp Pathol, 2013; 6(12): 2979-2988
Sugimoto KJ, Shimada A, Wakabayashi M, Imai H, Sekiguchi Y, Nakamura N, Sawada T, Ota Y, Takeuchi K, Ito Y,
Kimura H, Komatsu N, Noguchi M. A probable identical Epstein-Barr virus clone-positive composite lymphoma with
aggressive natural killer-cell leukemia
and cytotoxic T-cell lymphoma. Int J Clin Exp Pathol, 2013; 7(1): 411-417
Sugimoto KJ, Shimada A, Sakurai H, Wakabayashi M, Imai H, Sekiguchi Y, Nakamura N, Sawada T, Izumi H, Ota Y,
Komatsu N, Noguchi M. Primary gingival diffuse large B-cell lymphoma: a case report and a review of the
literature. Int J Clin Exp Pathol, 2013;
7(1): 418-424
Sekiguchi Y, Matsuzawa N, Shimada A, Imai H, Wakabayashi M, Sugimoto K, Nakamura N, Sawada T, Izutsu K, Takeuchi
K, Ohta Y, Komatsu N, Noguchi M. Angioimmunoblastic T-cell lymphoma with intramedullary production of
platelet-derived growth factor and possibly
complicating myelofibrosis: report of a case with review of the literature. Int J Hematol, 2013; 98(2): 250-257
Sekiguchi Y, Asahina T, Shimada A, Imai H, Wakabayashi M, Sugimoto K, Nakamura N, Sawada T, Komatsu N, Noguchi
M. A case of extramedullary plasmablastic plasmacytoma successfully treated using a combination of thalidomide
and dexamethasone and a review
of the medical literature. J Clin Exp Hematop, 2013; 53(1): 21-28
Sekiguchi Y, Shimada A, Imai H, Wakabayashi M, Sugimoto K, Nakamura N, Sawada T, Komatsu N, Noguchi M. CD56+
angioimmunoblastic T-cell lymphoma with evans syndrome : a case report and review of the literature. J Clin Exp
Hematop, 2013; 53(1): 37-47
Sekiguchi Y, Yoshikawa H, Shimada A, Imai H, Wakabayashi M, Sugimoto K, Nakamura N, Sawada T, Takeuchi K, Ohta
Y, Komatsu N, Noguchi M. Primary hepatic circumscribed Burkitt's lymphoma that developed after acute
hepatitis B: report of a case with a review
of the literature. J Clin Exp Hematop, 2013; 53(2): 167-173
Suzuki HI, Matsuyama H, Noguchi M, Yao T, Komatsu N, Mano H, Sugimoto K, Miyazono K. Computational dissection of
distinct microRNA activity signatures associated with peripheral T-cell lymphoma subtypes. Leukemia, 2013;
27(10): 2107-2111
Sasaki M, Sugimoto K. Entral nervous system recurrence in the primary mediastinal large B-cell lymphoma. Tumors
of the Central Nervous System, Springer, 2013; 9
Ichikawa K, Noguchi M, Masuda M, Tsutsui M, Sugimoto K, Sekiguchi Y, Imai H, Wakabayashi M, Komatsu N. CD4(+)
CD8(-) T cell large granular lymphocytic leukaemia with central nervous system involvement. Histopathology.
60(3): 519-522, 2012
Isobe Y, Aritaka N, Setoguchi Y, Ito Y, Kimura H, Hamano Y, Sugimoto K, Komatsu N. T/NK cell type chronic active
Epstein-Barr virus disease in adults: an underlying condition for Epstein-Barr virus-associated T/NK-cell
lymphoma. J Clin Pathol. 65(3):278-282,
2012
Kanemitsu N, Isobe Y, Masuda A, Momose S, Higashi M, Tamaru J, Sugimoto K, Komatsu N. Expression of Epstein-Barr
virus-encoded proteins in extranodal NK/T-cell Lymphoma, nasal type (ENKL): differences in biologic and clinical
behaviors of LMP1-positive
and -negative ENKL. Clin Cancer Res. 18(8):2164-2172, 2012
Isobe Y, Tomomatsu J, Tsukune Y, Tsukada N, Sasaki M, Sugimoto K, Komatsu N. Diagnostic Problems Among Chronic
Lymphocytic Leukemia and Other Indolent B-cell Leukemias in a Japanese Population. Intern Med. 51(15):
1977-1981, 2012
Tsutsui M, Koike M, Komatsu N. Fulminant hepatitis possibly caused by L-asparaginase during induction
chemotherapy in a patient with acute lymphoblastic leukemia. Rinsho Ketsueki. 53(5):531-4. Japanese. 2012
Tomomatsu J, Hamano Y, Ando J, Komatsu N, Sugimoto K. Non-myeloablative allogenic BMT for myelodysplastic
syndrome successfully controlled accompanying relapsing polychondritis. Bone Marrow Transplant. 47(5):742-743,
2012
Sekiguchi Y, Shirane S, Imai H, Sugimoto K, Wakabayashi M, Sawada T, Chigira N, Ichikawa K, Komatsu N, Noguchi
M. Response to low-dose bortezomib in plasma cell leukemia patients with malignant pleural effusion and ascites:
a case report and a review
of the literature. Intern Med. 51(11):1393-1398, 2012
Aritaka N, Ichikawa K, Nakamura H, Yasuda H, Ogura K, Matsumoto T, Komatsu N, Hirano T. Attainment of a
stringent complete response in multiple myeloma with thalidomide monotherapy. Intern Med. 51(19): 2781-2783,
2012
2011年
Ichikawa K, Noguchi M, Imai H, Sekiguchi Y, Wakabayashi M, Sawada T, Komatsu N. A case of T cell prolymphocytic
leukemia involving blast transformation. Int J Hematol. 93(5):667-672, 2011
Ichikawa K, Sugimoto K, Sato E, Sunami Y, Watanabe N, Ushimi T, Komatsu N. 18F-Fluorodeoxyglucose positron
emission tomography/computed tomography revealed the presence of simultaneous colon cancer in mucosa-associated
lymphoid tissue lymphoma. Geriatr
Gerontol Int. 11(4): 537-538, 2011
Sasaki M, Sugimoto K, Masuda A, Tsukune Y, Yahata Y, Komatsu N. Early CNS relapse in a good-risk primary
mediastinal large B-cell lymphoma after combined chemo- and radio-therapy. J Neurooncol. 99(2): 295-296, 2011
Yasuda H, Aritaka N, Ando J, Hirama M, Komatsu N, Hirano T. Chonic myelogenous leukemia with mild basophilia as
the predominant manifestation at presentation. Intern Med. 50(5):501-502, 2011
Tabe Y, Kawase Y, Miyake K, Satoh N, Aritaka N, Isobe Y, Oshimi K, Komatsu N, Miida T, Ohsaka A. Identification
of Bcl-2/IgH fusion sequences using real-time PCR and chip-based microcapillary electrophoresis. Clin Chem Lab
Med. 49(5):809-815, 2011
Inoue T, Sugiyama D, Kurita R, Oikawa T, Kulkeaw K, Kawano H, Miura Y, Okada M, Suehiro Y, Takahashi A, Marumoto
T, Inoue H, Komatsu N, Tani K. APOA-1 is a Novel Marker of Erythroid Cell Maturation from Hematopoietic Stem
Cells in Mice and Humans. Stem
Cell Rev. Stem Cell Rev. 7(1): 43-52, 2011
Sekiguchi Y, Imai H, Wakabayashi M, Sawada T, Ichikawa K, Komatsu N, Noguchi M. CD5-Positive Follicular
Lymphoma: A Case Report and Literautre Review. Intern Med. 50: 1-6, 2011
Matsuyama H, Suzuki HI, Nishimori H, Noguchi M, Yao T, Komatsu N, Mano H, Sugimoto K, Miyazono K. miR-135b
mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell
lymphoma. Blood 118(26):6881-6892, 2011
Morishita S, Komatsu N, Kirito K, Koda AH, Sekiguchi Y, Tsuneda S, Noda N. Alternately binding probe competitive
PCR as a simple, cost-effective, and accurate quantification method for JAK2V617F allele burden in
myeloproliferative neoplasms. Leuk Res.
35(12):1632-1636, 2011
Iwata S, Yano S, Ito Y, Ushijima Y, Gotoh K, Kawada JI, Fujiwara S, Sugimoto K, Isobe Y, Nishiyama Y, Kimura H.
Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of epstein-barr
virus infection. Int J Cancer.
129(9): 2263-2273, 2011
Sunami Y, Sato E, Ichikawa K, Yasuda H, Komatsu N. Hemorrhagic colitis caused by dasatinib following
cytomegalovirus enterocolitis in a patient with chronic myelogenous leukemia in the second chronic phase. Rinsho
Ketsueki. 52(5): 282-286, Japanese. 2011
Takagi S, Komatsu N. Risk-benefit assessment in management of adult idiopathic thrombocytopenic purpura. Rinsho
Ketsueki. 52(11): 1751-1758, Japanese. 2011